

**EXPLORING THE POTENTIAL OF OPTIMISED STARCH
PARTICULATES AS PLATFORM FOR ORAL DELIVERY
OF A MODEL GASTROLABILE DRUG CEFOTAXIME**

by

NADEEM IRFAN BUKHARI

**Thesis submitted in fulfilment of the
requirements for the degree
of Doctor of Philosophy**

2009

ACKNOWLEDGEMENT

I would like to express my sincere gratitude to my supervisor, Professor Dr. Saringat Haji. Bai, School of Pharmacy, Universiti Sains Malaysia (USM), Penang for his scientific guidance, insightful discussion, for allowing me to develop my work in higher tier research approaches and for giving me the freedom to develop my own ideas.

I am indebted to my co-supervisor Professor Dr. Yuen Kah Hay, School of Pharmacy, USM, Penang for his incessant support, guidance, encouragement and attention to detail rigor for helping me throughout my PhD. Through his supervision, I have gained a lot more than scientific development.

My sincere gratitude is for my Field Supervisor, Professor Dr. Abu Bakar Abdul Majeed, Dean Faculty of pharmacy, Universiti Teknologi Mara (UiTM), Kuala Selangor, Malaysia for his invaluable logistic input, intellectual support and constant interest in the PhD work and making UiTM research facilities available.

I am also indebted to Professor Dr. Peter Pook, Dean School of Pharmacy and Allied Sciences, International Medical University (IMU), Kuala Lumpur for grant of the protected time, suggestion and cooperation during my research work. Part of the investigations for this study has been undertaken within the scope of research projects funded by International Medical University (vide grants, IMU 069/04 and IMU 108/06). The above fundings are gratefully acknowledged.

I am thankful to Professor Dr. Oya Alpar, School of Pharmacy, University of London, UK for providing me opportunity to work with her research group on new drug delivery systems and for her generous support during research work at School of Pharmacy,

University of London, UK. I am thankful to Dr. Gabriele Anisah Froemming, Head Institute of Medical Molecular Biotechnology (IMMB), UiTM for permission for Scanning Electron Microscopy (SEM) and Mr. Abdul Karim, at IMMB, UiTM and David McCarthy at Electron Microscopy Unit, School of Pharmacy, University of London for carrying out SEM.

The start of this work is much owing to the cooperation of my friends, Dr. Nisar ur Rehman, Associate Professor, Islamia University, Bhawalpur Pakistan and Waseem Sarwar, Manager Research and Development, Highnoon Laboratories, Lahore-Pakistan. I am also thankful to Khalid Ahmad Sheikh, Lecturer, IMU for his encouragement and interesting discussions. I pay thanks to Dr Rosa Elizabeth Pereira, then PhD scholar at UiTM and Mr. Tommy Julianto, Lecturer, UiTM for their informal discussions. I am also thankful to Dr. Rosa for her help in HPLC method validation, Dr. Adhiyaman Rajendran, Lecturer Pharmaceutics, IMU for help in kinetic analysis of drug release and Khalid Hussain, PhD scholar, USM for his help during pharmacokinetic studies.

Special thanks go to Shari Kraber, Wayne F. Adams and Mark J. Anderson, Stat Ease Inc., Minneapolis, USA and Colbourn Elizabeth, Intelligensys, Ltd., UK for their email discussions on the predictive model development and data analysis and data visualization. I also appreciate Pharsight Corporation, Mountain View, CA, USA for providing WinNonlin[®] Ver 5.2.1 under the Pharsight Academic Licence programme.

I am also deeply thankful to my siblings who are always there for me and for reminding me that my research should serve good purposes for all humankind. My spouse has been very supportive for this work. Her understanding and moral support during my work has been very much appreciated. I am also thankful to her for weathering through and forgiving my bouts of moans and whines and thank to her for hanging in there with me during the hard times. This work is dedicated to her and to our sons, Muhammad Haris Bukhari, Muhammad Usama Bukhari and particularly, to Muhammad Qasim Bukhari.

Last, but not the least, I thank my heavenly parents, for their efforts to give me the best training, educating me and for unconditional support and encouragement to pursue my interests. They never leave me aside and never once allowed my foot to slip. Their prayers have always been with me.

Nadeem Irfan Bukhari,
B.Pharm., M.Phil Pharm. (Pak)

TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENT	ii
TABLE OF CONTENTS	v
LIST OF TABLES	xx
LIST OF FIGURES	xxii
LIST OF PLATES	xxviii
LIST OF SYMBOLS	xxix
LIST OF ABBREVIATION	xxx
ABSTRAK	xxxiii
ABSTRACT	xxxv
CHAPTER 1 – GENERAL INTRODUCTION AND AIMS OF STUDY	1
1.1 THE ORAL ROUTE OF ADMINISTRATION	1
1.1.1 Drug absorption after oral route of administration	1
1.1.2 Barriers to drug absorption after oral administration	2
1.1.2(a) Gastrointestinal tract milieu	2
1.1.2(b) Mucus	3
1.1.2(c) Epithelial cells – the mechanical barrier on lumen side	3
1.1.2(d) Epithelial permeation, transport pathways and mechanisms	3
1.1.2(e) Efflux transporters and pumps	4
1.1.2(f) Endothelial cells – the mechanical barrier on apical side	5
1.1.2(g) Presystemic cellular metabolism	5
1.1.2(h) Presystemic hepatic metabolism	5
1.1.2(i) Enterohepatic shunt	6
1.2 STRATEGIES TO OVERCOME BARRIERS FOR ORAL DELIVERY	6
1.2.1 Approaches addressing gastric liability	6
1.2.1(a) Chemical modification – prodrug and drug analogue	7
1.2.1(b) Lipidisation strategies	7
1.2.1(c) Polymeric coating, encapsulation or entrapment	8
1.2.1(d) Drug targeting to lymphatics	8
1.2.1(e) Drug targeting to the Peyer’s patches	9
1.2.1(f) Targeted drug delivery to colon	10
1.2.1(g) General use of particulate drug carriers	11
1.3 PARTICULATE DELIVERY SYSTEMS	11

1.3.1	Liposomes	12
1.3.2	Solid lipid nanoparticles	13
1.4	GENERAL METHODS FOR PREPARATION OF PARTICULATES	13
1.4.1	Bottom-up procedures	13
1.4.1(a)	Emulsion/dispersion polymerization	13
1.4.1(b)	Preparation from preformed polymers	14
1.4.1(c)	Solvent deposition/displacement (nanoprecipitation)	15
1.4.1(d)	Emulsification-cross-linking	16
1.4.1(e)	Desolvation of macromolecules	16
1.4.2	Supercritical fluid technology	16
1.4.3	Top-down procedure	17
1.4.3(a)	Extrusion	17
1.4.3(b)	Wet-grinding (nanomilling)	17
1.4.4	Materials of fabrication of particulates	17
1.5	GENERAL APPLICATIONS OF PARTICULATES	18
1.5.1	Oral delivery of peptides, gastrolabile drugs and vaccines	18
1.5.2	Targeting infected and inflamed cells	18
1.5.3	Targeting cytostatics to tumours	19
1.5.4	Ophthalmic delivery	19
1.5.5	Vaginal drug delivery	19
1.5.6	Enhancing drug safety	19
1.5.7	Adjuvants for vaccines	20
1.6	STARCH AS THE MATERIAL OF PARTICULATE FABRICATION	20
1.6.1	Starch composition and molecular structure	21
1.6.1(a)	Amylose	21
1.6.1(b)	Amylopectin	21
1.6.1(c)	Molecular arrangement of amylose and amylopectin	21
1.6.1(d)	Other minor components	22
1.6.2	Types of starches	22
1.6.2(a)	Modified starches	22
1.6.3	Functionality of starch	23
1.6.3(a)	Gelatinisation	23
1.6.3(b)	Hydrocolloidal functionality	23
1.6.3(c)	Thickening agent	24
1.6.3(d)	Gel and film formation	24
1.6.3(e)	Retrogradation	24

1.6.3(f)	Water binding capacity	25
1.6.4	Features of starch usable in new and novel drug delivery systems	25
1.6.5	New and novel starch-based delivery systems	26
1.6.6	Applications of new and novel starch-based systems	26
1.6.6(a)	Enhanced pharmaceutical excipient	26
1.6.6(b)	Delivery carrier	26
1.6.6(c)	Control release	27
1.6.6(d)	Bioadhesive drug delivery system	27
1.6.6(e)	Regional chemotherapy	28
1.6.6(f)	Miscellaneous	28
1.6.7	Methods for the fabrication of starch particulates	28
1.7	MODEL DRUG AND THE MATERIAL OF FABRICATION	28
1.7.1	Cefotaxime sodium as model drug	28
1.7.2	Starch as the material of fabrication	32
1.8	MULTIVARIABLE OPTIMISATION	33
1.8.1	Statistical optimisation algorithms	33
1.8.2	Artificial intelligent optimisation algorithms	35
1.9	Problem statement	36
1.10	Experimental work and the scope of study	37
	 CHAPTER 2 – HPLC METHOD VALIDATION AND STABILITY STUDIES OF CEFOTAXIME SODIUM	 38
2.1	INTRODUCTION	38
2.1.1	Validation of HPLC method	38
2.1.1(a)	Specificity	38
2.1.1(b)	Linearity	39
2.1.1(c)	Accuracy	39
2.1.1(d)	Precision	39
2.1.1(e)	Sensitivity	40
2.1.1(f)	Robustness	40
2.1.2	Stability studies of cefotaxime sodium	40
2.1.3	Objectives of the study	41
2.2	EXPERIMENTAL FOR HPLC	41
2.2.1	Materials	41
2.2.2	HPLC instrumentation	42
2.2.2(a)	Mobile phase	42

2.2.2(b)	HPLC conditions	42
2.2.2(c)	Preparation of cefotaxime sodium standard solution	42
2.2.2(d)	Preparation of drug-spiked plasma	43
2.2.2(e)	Processing of the plasma-spiked samples	43
2.2.3	Method validation	44
2.2.3(a)	Assessment of specificity	44
2.2.3(b)	Determination of linearity and range	44
2.2.3(c)	Evaluation of accuracy and precision	44
2.2.3(d)	Estimation of recovery	44
2.2.3(e)	Sensitivity	45
2.3	ASSESSMENT OF DRUG STABILITY	45
2.3.1	Chemicals	45
2.3.2	Software tool	45
2.3.3	Assessment of stability	46
2.3.3(a)	Preparation of drug aqueous solutions with different pH values	46
2.3.3(b)	Preparation of glutaraldehyde and amylase solutions	46
2.3.3(c)	Sample incubation, collection and processing	47
2.3.3(d)	Analysis of cefotaxime sodium concentration in samples	47
2.3.3(e)	Data analysis	47
2.3.3(f)	Selection of the predictive model	48
2.4	RESULTS	48
2.4.1	HPLC method validation	48
2.4.1(a)	Specificity	48
2.4.1(b)	Linearity	49
2.4.1(c)	Recovery, accuracy and precision	49
2.4.1(d)	Sensitivity	50
2.4.2	Stability of cefotaxime sodium	50
2.4.2(a)	Drug stability in aqueous solutions at different pH values	51
2.4.2(b)	Stability of drug in different preparatory media	51
2.5	DISCUSSION	53
2.5.1	HPLC	53
2.5.2	Stability study of cefotaxime sodium	54
2.6	CONCLUSION	56

CHAPTER 3 – FABRICATION OF STARCH PARTICULATES BY SPRAY DRYING	57
3.1 INTRODUCTION	57
3.1.1 Advantages of spray-drying	58
3.1.2 Applications of spray-drying in developing starch particulates	59
3.1.3 Objectives of the study	59
3.2 EXPERIMENTAL	60
3.2.1 Materials	60
3.2.2 Software tool	60
3.2.3 Methods	60
3.2.3(a) Experimental design	60
3.2.3(b) Preparation of starch premixes	61
3.2.3(c) Spray-drying of starch premixes	61
3.2.3(d) Determination of particle size	61
3.2.3(e) Determination of size distribution (dispersion in uniformity)	62
3.2.3(f) Measurement zeta potential	62
3.2.3(g) Determination of particle yield	62
3.2.3(h) Data analysis and selection of the predictive model	62
3.2.3(i) Scanning electron microscopy of starch particles	63
3.2.3(j) Optimisation of responses and selection criteria	63
3.2.3(k) Validation of predicted formulation	63
3.3 RESULTS	64
3.3.1 Particle size	65
3.3.2 Dispersion in uniformity of particle size	66
3.3.3 Zeta potential	68
3.3.4 Powder yield	68
3.3.5 Simultaneous optimisation and validation	70
3.3.6 Scanning electron micrographs of corn starch particles	71
3.4 DISCUSSION	71
3.4.1 Experimental design	71
3.4.2 Factors and experimental conditions	71
3.4.3 Data analysis and model selection	73
3.4.3(a) Particle size	74
3.4.3(b) Uniformity of size distribution	75
3.4.3(c) Zeta potential	75
3.4.3(d) Powder yield	75

3.4.4	Optimisation and validation	76
3.4.5	Scanning electron micrographs of corn starch particles	76
3.5	CONCLUSION	77
CHAPTER 4 – FABRICATION OF STARCH PARTICULATES BY ULTRASONICATION		78
4.1	INTRODUCTION	78
4.1.1	Ultrasonication	79
4.1.1(a)	Possibility of size reduction with ultrasonication	80
4.1.2	Objectives of the study	80
4.2	EXPERIMENTAL	81
4.2.1	Materials	81
4.2.2	Instruments	81
4.2.2(a)	Homogenizer	81
4.2.2(b)	Probe sonicator	81
4.2.2(c)	Software tool	81
4.2.3	Methods	81
4.2.3(a)	Experimental design	81
4.2.3(b)	Construction of design layout for optimisation	82
4.2.3(c)	Preparation of starch premixes	82
4.2.3(d)	Ultrasonication of starch premixes	83
4.2.3(e)	Determination of particle size and polydispersity index (PDI)	83
4.2.3(f)	Measurement of zeta potential	84
4.2.3(g)	Data analysis	84
4.2.3(h)	Predictive model selection in optimisation study	85
4.2.3(i)	Optimisation criteria	85
4.2.3(j)	Assessment of model validation and output reproducibility	86
4.3	RESULTS	86
4.3.1	Pre-optimisation study	86
4.3.1(a)	Pulsed ultrasonication	86
4.3.1(b)	Continuous ultrasonication	88
4.3.1(c)	Effect of phospholipid	90
4.3.1(d)	Effect of ultrasonication time and phospholipid concentration	91
4.3.1(e)	Effect of surfactants	92
4.3.1(f)	Effect of stabilizers	94
4.3.2	Optimisation study	94

4.3.2(a)	Optimisation of factors for particle size	95
4.3.2(b)	Optimisation of factors for polydispersity index (PDI)	100
4.3.2(c)	Optimisation of factors for zeta potential	104
4.3.2(d)	Simultaneous optimisation of all responses and validation of prediction	105
4.4	DISCUSSION	106
4.4.1	Pre-optimisation study	106
4.4.1(a)	Factors in study	106
4.4.1(b)	Effect of pulse ultrasonication	107
4.4.1(c)	Effect of continuous ultrasonication	107
4.4.1(d)	Effect of phospholipid	108
4.4.1(e)	Effect of phospholipid with continuous ultrasonication	108
4.4.1(f)	Effect of surfactants	109
4.4.1(g)	Effect of stabilisers	109
4.4.2	Optimisation study	110
4.4.2(a)	Experimental design – D-optimal	110
4.4.2(b)	Data analysis in optimisation study	110
4.4.2(c)	Predictability of model	111
4.4.2(d)	Particle size	112
4.4.2(e)	Polydispersity index	113
4.4.2(f)	Zeta potential	113
4.4.2(g)	Simultaneous optimisation	113
4.4.2(h)	Validation of predicted formulation	114
4.4.3	Comment on ultrasonication as method of size reduction	114
4.4.3(a)	Mechanisms for size reduction by ultrasonication	114
4.5	CONCLUSION	115
CHAPTER 5 – STARCH PARTICULATES BY NANOMILLING: A PRE-EXPERIMENTAL PILOT STUDY		117
5.1	INTRODUCTION	117
5.1.1	Objectives of the study	119
5.2	EXPERIMENTAL	120
5.2.1	Materials	120
5.2.2	Grinding media	120
5.2.3	Instrumentation	120
5.2.4	Methods	120

5.2.4(a)	Preparation of starch premixes	120
5.2.4(b)	Nanomilling of starch premixes	121
5.2.4(c)	Determination of size and polydispersity index (PDI)	124
5.2.4(d)	Measurement of zeta potential	124
5.2.4(e)	Data analysis	125
5.2.4(f)	Selection of appropriate formulation parameters for optimisation study	125
5.3	RESULTS	125
5.3.1	Milling time	126
5.3.2	Heating the starch premixes	126
5.3.3	Addition of surfactants	128
5.3.3(a)	Pluronic-F68	128
5.3.3(b)	Addition of Spans and Tweens at different concentrations	128
5.3.4	Addition of cross-linker and plasticizer at varied cross-linking reaction times	131
5.3.5	Change of grinding media (beads) size	132
5.3.6	Addition of amylase	133
5.3.7	Change of starch content	134
5.3.8	Variation in pH	135
5.3.9	Omission of glycerol at pH 5.5	136
5.3.10	Addition of surfactants and other dispersant	137
5.3.10(a)	Addition of PEG as dispersant	137
5.3.10(b)	Addition of different surfactants with different concentrations at pH 5.0	138
5.3.11	Selection of suitable formulation parameters and process conditions	140
5.4	DISCUSSION	141
5.4.1	Effect of milling time	142
5.4.2	Effect of heating starch premixes	143
5.4.3	Effect of addition of surfactants	144
5.4.4	Effect of addition of cross-linker and plasticizer	145
5.4.5	Effect of changing grinding media	147
5.4.6	Effect of addition of amylase	148
5.4.7	Effect of changing the starch contents	148
5.4.8	Effect of variation of pH	148
5.4.9	Effect of omission of glycerol at pH 5.5	149
5.4.10	Effect of dispersant, PEG and other surfactants	149
5.4.11	Identification and selection of critical factors	150

5.5	CONCLUSION	151
CHAPTER 6 – STARCH PARTICULATES BY NANOMILLING – OPTIMISATION STUDY		153
6.1	INTRODUCTION	153
	6.1.1 Objectives of the study	154
6.2	EXPERIMENTAL	154
	6.2.1 Materials	154
	6.2.2 Grinding media	155
	6.2.3 Instrumentation	155
	6.2.4 Software tool	155
	6.2.5 Methods	155
	6.2.5(a) Experimental design	155
	6.2.5(b) Preparation of starch premixes	156
	6.2.5(c) Nanomilling of the premixes	156
	6.2.5(d) Determination of particle size, PDI and zeta potential	157
	6.2.5(e) Data analysis and model selection	157
	6.2.5(f) Optimisation criteria	157
	6.2.5(g) Validation and assessment of reproducibility	157
6.3	RESULTS	157
	6.3.1 Pre-optimisation screening study	158
	6.3.1(a) Factors for particle size	158
	6.3.1(b) Factors for polydispersity index	163
	6.3.1(c) Factors for zeta potential	166
	6.3.2 Optimisation study	168
	6.3.2(a) Optimisation of factors for particle size	169
	6.3.2(b) Optimisation of factors for polydispersity index	170
	6.3.2(c) Optimisation of factors for zeta potential	173
	6.3.3 Simultaneous optimisation of particle size, PDI and zeta potential	174
6.4	DISCUSSION	175
	6.4.1 Factors and their levels in pre-optimisation and optimisation study	175
	6.4.2 Experimental designs	176
	6.4.3 Data analysis	177
	6.4.4 Model selection and testing predictability	177
	6.4.5 Particle size	178
	6.4.6 Polydispersity index	179

6.4.7	Zeta potential	180
6.4.8	Simultaneous prediction of optimum levels	181
6.4.9	Validation and reproducibility	181
6.5	CONCLUSION	182
CHAPTER 7 – <i>IN VITRO</i> CHARACTERISATION OF STARCH PARTICULATES AND DRUG RELEASE STUDY		183
7.1	INTRODUCTION	183
7.1.1	Particle size, distribution and surface charges	183
7.1.2	Drug loading analysis	183
7.1.3	<i>In vitro</i> drug release	184
7.1.4	Biological and other characterisation methodologies	185
7.1.5	Objectives of the study	186
7.2	EXPERIMENTAL	186
7.2.1	Materials	186
7.2.2	Methods	186
7.2.2(a)	Preparation and drug loading on optimised starch formulations	186
7.2.2(b)	Particle size, PDI/dispersion in uniformity and zeta potential	187
7.2.2(c)	Particle yield and drug loading analysis	187
7.2.2(d)	Quantification of drug in samples	188
7.2.2(e)	Scanning electron microscopy	188
7.2.2(f)	Swelling index	188
7.2.2(g)	Assessment of physical stability of optimised particles	189
7.2.2(h)	<i>In vitro</i> drug release study	189
7.2.2(i)	Kinetic analysis of release data	190
7.2.2(J)	Statistical data analysis	190
7.3	RESULTS	191
7.3.1	Particle size, PDI and zeta potential	192
7.3.2	Particulate recovery (yield) and loading efficiency	192
7.3.3	Scanning electron micrographs of starch particulates	193
7.3.4	Degree of swelling	193
7.3.5	Physical stability	195
7.3.6	Release kinetics	198
7.4	DISCUSSION	200
7.4.1	Particle size, PDI and zeta potential of blank and loaded particles	200
7.4.2	Drug loading	201

7.4.3	Scanning electron micrographs of starch particles	202
7.4.4	Swelling index	202
7.4.5	Physical stability	203
7.4.6	Kinetics of <i>in vitro</i> drug release	203
7.5	CONCLUSION	204
 CHAPTER 8 – BIOAVAILABILITY AND PHARMACOKINETIC STUDY OF CEFOTAXIME SODIUM LOADED STARCH PARTICULATE CARRIERS		205
8.1	INTRODUCTION	205
8.1.1	Pharmacokinetic properties of and issues for cefotaxime sodium	206
8.1.2	Approaches for improving of bioavailability of cefotaxime sodium	206
8.2	Objectives of the study	207
8.3	EXPERIMENTAL	207
8.3.1	Materials	207
8.3.2	Experimental animals and their housing prior to experimentation	207
8.3.3	Methods	208
8.3.3(a)	Experimental design	208
8.3.3(b)	Preparation of aqueous drug solution and starch vehicles	209
8.3.3(c)	Preparation and characterisation of starch particulate formulations	209
8.3.3(d)	Administration of dose	210
8.3.3(e)	Blood sampling and sample processing	210
8.3.3(f)	Determination of drug in biological samples	210
8.3.3(g)	Pharmacokinetic data analysis	211
8.3.3(h)	Statistical data analysis	211
8.4	RESULTS	211
8.4.1	Particle size and their characterisation	211
8.4.2	Plasma level time curves	212
8.4.3	Pharmacokinetic parameters	213
8.5	DISCUSSION	219
8.5.1	Study design	219
8.5.2	Pharmacokinetics computation approach	220
8.5.3	Characteristics of the particulate formulations	221
8.5.4	Plasma level time curves and derived parameters	221
8.5.4(a)	Appearance of double peak phenomenon	222

8.5.4(b)	Pharmacokinetics parameters	223
8.5.5	Enhanced oral bioavailability of cefotaxime sodium	224
8.5.6	Possible reasons for enhanced oral bioavailability	225
8.5.6(a)	Protective effects of starch	226
8.5.6(b)	Macromolecular/drug endocytosis	226
8.5.6(c)	Starch absorption and transport	226
8.5.6(d)	Particulate characteristics	227
8.5.6(e)	Mucoadhesion	228
8.5.6(f)	Presence of surfactant (composition)	229
8.5.6(g)	Co-grinding (processing)	229
8.5.7	<i>In vivo</i> release mechanisms from particulates	229
8.5.7 (a)	Digestibility of starch– a basis for drug release from starch	230
8.6	CONCLUSION	231
 CHAPTER 9 – GENERAL DISCUSSION, CONCLUSION AND SUGGESTIONS FOR IMPROVEMENT AND FURTHER DEVELOPMENT		232
9.1	GENERAL DISCUSSION	232
9.1.1	HPLC method validation and drug stability assessment	232
9.1.2	Production methods for starch particulates	233
9.1.3	Use of computer-aided optimisation algorithms	234
9.1.4	Important features of starch particles	234
9.1.5	<i>In vitro</i> characterisation, drug loading and particle shape	235
9.1.6	Bioavailability and pharmacokinetics	235
9.2	ENVISIONED BIOMEDICAL APPLICATIONS SUITABLE FOR THIS SYSTEM	236
9.2.1	Lymph targeting	236
9.2.2	Application for other drugs	236
9.2.3	Tumour therapy	236
9.2.4	Local periodontal delivery carrier	236
9.2.5	Pharmaceutical excipient	237
9.2.6	Future of starch particulates	237
9.3	SUGGESTIONS FOR IMPROVEMENTS AND FURTHER DEVELOPMENT	237
9.3.1	Spray-drying	238
9.3.2	Ultrasonication	238
9.3.3	Nanomilling	238

9.3.4	Polydispersity	239
9.3.5	Drug loading	239
9.3.6	Physical stability	240
9.3.7	<i>In vitro</i> drug release	240
9.3.8	Microscopic, radiopharmaceutical and pharmacokinetic evaluation	240
9.3.9	Assessment of therapeutic potential	240
9.3.10	Miscellaneous	241
BIBLIOGRAPHY		242
APPENDICES		
A 2.1	Data on the stability of cefotaxime sodium in different experimental conditions	273
A 3.1	Data for particle size, polydispersity index, zeta potential of corn starch based on DX [®] generated template	274
A 3.2	Predicted levels of factors to prepare optimised corn starch particles using spray-drying	275
A 4.1	Effect of pulsed ultrasonication on the particle size and polydispersity index of potato starch, soluble starch and corn starch	276
A 4.2	Effect of continuous ultrasonication on the particle size and polydispersity index of potato starch, soluble starch and corn starch	277
A 4.3	Effect of different concentrations of phospholipid on the particle size of potato starch. (SD is given in parentheses)	278
A 4.4	Effect of different concentrations of phospholipid on the particle size of soluble starch particles. (SD is given in parentheses)	279
A 4.5	Effect of different concentrations of phospholipid on the particle size of corn starch particles. (SD is given in parentheses)	280
A 4.6	Effect of different concentrations of phospholipid on the polydispersity index of potato starch particles. (SD is given in parentheses)	281
A 4.7	Effect of different concentrations of phospholipid on the polydispersity index of soluble starch particles. (SD is given in parentheses)	282
A 4.8	Effect of different concentrations of phospholipid on the polydispersity index (PDI) of corn starch. (SD is given in parentheses)	283
A 4.9	Effect of surfactants at different concentrations on the particle size and polydispersity index of potato starch, soluble starch and corn starch	284
A 4.10	Effect of stabilizers on the particle size, polydispersity index and zeta charge of potato starch, soluble starch and corn starch	285
A 4.11	Particle size, polydispersity index and zeta charge of particles prepared following DX [®] - generated combinations for factors in optimisation study	286
A 4.12	Predicted levels and responses generated by DX [®] 7.1.5 for ultrasonication	287

A 5.1	Effect of milling time and heat on the particle size and polydispersity index of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	288
A 5.2	Effect of surfactants at different concentrations on the particle size and polydispersity index of potato starch, soluble starch and corn starch at pH 10.0. Mean \pm SD, N = 3.	289
A 5.3	Effect of the time of cross-linking on the particle size and polydispersity index of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	290
A 5.4	Effect of the size of media (beads) on the particle size and polydispersity index of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3	290
A 5.5	Effect of addition of amylase on the particle size and polydispersity index of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	290
A 5.6	Effect of different starch content on the particle size and polydispersity index of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	290
A 5.7	Effect of pH of the starch premixes on the size and polydispersity index of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	291
A 5.8	Effect of omission of glycerol at pH 5.5 on the size and polydispersity index of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	291
A 5.9	Effect of addition of PEG on the size and polydispersity index of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	291
A 5.10	Effect of surfactants with different concentrations at pH 5.5 on the particle size and polydispersity index of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	292
A 6.1	Size, polydispersity index and zeta potential of the formulations prepared using the pre-optimisation screening design	293
A 6.2	Predicted levels of the factors and responses for optimized potato starch particles formulations	295
A 6.3	Particle size, polydispersity index and zeta potential of the validation formulations of potato starch	295
A 7.1	Effect of drug loading and storage on the particle size, polydispersity index and zeta potential of potato starch particulates. Mean \pm SD, N = 4.	296
A 7.2	Effect of drug loading and storage on the particle size, polydispersity index and zeta potential of soluble starch particulates. Mean \pm SD, N = 4.	297
A 7.3	Effect of drug loading on the size of corn starch particulates	298
A 7.4	The p-value for the particle size, polydispersity index (PDI) and zeta potential when blank and drug loaded starch particulate formulations compared at zero to day 7	298
A 7.5	Loading efficiency of different starch particles	299
A 7.6	The p-value for the yield, loading and loading efficiency when blank and loaded starch particulate formulations were compared	299
A 7.7	Zeta potential of the different processing ingredients used in this study	299
A 8.1	Approval letter from Animal Ethics Committee to carry out bioavailability and pharmacokinetic study	300

A 8.2	Pharmacokinetic parameters of cefotaxime sodium after single oral dose of C_{AQUEOUS} , as free drug (control) to male Sprague-Dawley rats	301
A 8.3	Pharmacokinetic parameters of cefotaxime sodium after single oral dose of drug containing potato starch vehicle ($C_{\text{VEHICLE-PS}}$) to male Sprague-Dawley rats	301
A 8.4	Pharmacokinetic parameters of cefotaxime sodium after single oral dose of drug loaded cross-linked potato starch ($F_{\text{PS-CL}}$) to male Sprague-Dawley rats	302
A 8.5	Pharmacokinetic parameters of cefotaxime sodium after single oral dose of drug loaded uncross-linked potato starch ($F_{\text{PS-UCL}}$) to male Sprague-Dawley rats	302
A 8.6	Pharmacokinetic parameters of cefotaxime sodium after single oral dose of drug containing soluble starch vehicle ($C_{\text{VEHICLE-SS}}$) to male Sprague-Dawley rats	303
A 8.7	Pharmacokinetic parameters of cefotaxime sodium after single oral dose of drug loaded uncross-linked cationic soluble starch particulates ($F_{\text{SS-UCL}^+}$) to male Sprague-Dawley rats	303
A 8.8	Pharmacokinetic parameters of cefotaxime sodium after single oral dose of drug loaded uncross-linked anionic soluble starch particulates ($F_{\text{SS-UCL}^-}$) to male Sprague-Dawley rats	304
A 8.9	Pharmacokinetic parameters of cefotaxime sodium after single oral dose of drug loaded uncross-linked neutral soluble starch particulates ($F_{\text{SS-UCL}^0}$) to male Sprague-Dawley rats	304
A 8.10	Pharmacokinetic parameters of cefotaxime sodium after single oral dose of drug loaded spray-dried cross-linked corn starch ($F_{\text{CS-SpD}}$) to male Sprague-Dawley rats	305
A 8.11	The p-values for the pharmacokinetic parameters of potato starch controls and the potato starch particulate formulations	305
A 8.12	The p-values for the pharmacokinetic parameters of soluble starch controls and the soluble starch particulate formulations	306
A 8.13	The p-values for the pharmacokinetic parameters of corn starch particles ($F_{\text{CS-SpD}}$) and aqueous drug control (C_{AQUEOS}) and, between particles of potato starch ($F_{\text{PS-UCL}}$) and soluble starch ($F_{\text{SS-UCL}^+}$)	306
12 LIST OF PUBLICATIONS AND AWARDS		307

LIST OF TABLES

Table	Page
1.1 Review of the methods used for development of starch particulates	29
2.1 Physicochemical properties of cefotaxime sodium	41
2.2 Multiple response optimisation criteria for the stability of cefotaxime sodium	47
2.3 The recovery, within- and between-day precision and accuracy for cefotaxime sodium	50
2.4 The values of R ² , LOD and LOQ cefotaxime sodium	50
3.1 The fixed and varied experimental conditions	61
3.2 Experimental design matrix for 4 factors each at 3 levels with response variables	64
3.3 ANOVA statistics of screening design for particle size, dispersion in uniformity, zeta potential and yield	65
3.4 Numerical goodness of fit statistical criteria for response data of corn starch	66
3.5 Comparison of validation formulations with the predicted formulations	71
4.1 Particle size, polydispersity index (PDI) and zeta potential on the starch particulates of potato starch, soluble starch and corn starch. Mean ± SD, N = 3.	96
4.2 ANOVA statistics of screening design for particle size, polydispersity index and zeta potential of starches under study	97
4.3 Comparison of the validation formulations with the predicted formulation	106
5.1 Formulation variables and the processing conditions for premixes of potato starch, soluble starch and corn starch	122
5.2 Parameters and conditions found to be favourable for potato and soluble starch	141
5.3 Particle size, polydispersity index and zeta potential for soluble starch particles. Mean ± SD, N = 4.	141
6.1 The fixed and varied experimental conditions	156
6.2 Experimental design matrix for 7 factors, each at 2 levels (2 ⁷) along with the data for particle size, polydispersity index (PDI and zeta potential. Mean ± SD, N = 3.	159
6.3 ANOVA of screening design for particle size, polydispersity index and zeta potential	160
6.4 Complementary array of the low, middle and high levels for 7 factors along with the data for particle size, polydispersity index and zeta potential. Mean ± SD, N = 3.	169
6.5 ANOVA statistics of the optimisation design for particle size, polydispersity index and zeta charge of potato starch	170

Table	Page
6.6 Comparison of validation formulations with the predicted formulation	173
7.1 Composition of the starch particulate formulations selected for <i>in vivo</i> study	187
7.2 Description of the mathematical models used to describe drug release from potato starch particulate formulations	191
7.3 Particle size, polydispersity index and zeta potential of blank and drug loaded starch particulate formulations. Mean \pm SD, N = 4.	192
7.4 The swelling index of three starch and the selected starch particulates	195
7.5 Correlation coefficient (R^2) values in various kinetic models tested to describe drug release from different starch particulate formulations	200
7.6 Mean dissolution time of free drug in aqueous solution and that of the starch particulate formulations. Mean \pm SD, N = 6.	200
8.1 Detail on the comparison of bioavailability of starch particulate to that of controls	209
8.2 Statistical tests for comparing the control and starch particulate formulations	211
8.3 Particle size, polydispersity index and zeta potential for different starch particles under investigation. Mean \pm SD, N = 4.	212
8.4 Pharmacokinetic parameters of cefotaxime sodium after single oral dose of different drug loaded starch particles and controls to the male Sprague-Dawley rats. Mean \pm SD (in parentheses), N = 6.	216
8.5 The reported pharmacokinetic parameters of cefotaxime sodium in rats	225

LIST OF FIGURES

Figure		Page
1.1	Morphological and functional barriers for drug absorption after oral administration	2
1.2	Microvilli showing epithelial cells and underneath two circulatory systems, blood and lymphatic stream. A special transport mechanism, persorption is also shown	9
1.3	A suggested experimentation strategy for optimum design of experiment (DoE) (Adapted and modified from Anderson and Whitcomb, 2005)	34
1.4	Schematics for the architect of a neural network for the solution of complex problems	35
2.1	Chromatograms for blank (I) and spiked (II) rat plasma	49
2.2	Calibration curve of cefotaxime sodium	50
2.3	Response surface plot for effect of pH and time on percentage of drug remaining	52
2.4	Overlay plot with sweet spot showing optimised conditions for maximum drug stability (I). Interaction plot showing combined effect of pH and time on drug stability (II)	52
2.5	Artificial neural network (ANN)-generated response surface plot for the effect of pH and time on percentage of drug remaining	52
2.6	Drug remaining at pH 1.0, 4.0, 7.0 and 5.5 in aqueous solution. Mean \pm SD, N = 3.	53
2.7	Drug remaining in amylase and glutaraldehyde solution and at pH 10.0. Mean \pm SD, N = 3	53
3.1	A simplified diagram of the Buchi Mini Spray-Drier (Buchi Laboratotiums – Technik AG, Flawil, Switzerland) (Adapted and modified from Maa <i>et al.</i> , 1998)	58
3.2	Half-normal plot (I) and Pareto chart (II) indicating the critical factors for particle size of corn starch	66
3.3	Interaction plot showing combined effect of corn starch content and surfactant on particle size	67
3.4	Half-normal plot (I) and Pareto chart (II) indicating the critical factors for the dispersion in uniformity of particle size of corn starch	67
3.5	One factor plot showing the effect of the volume of DMSO on the dispersion in uniformity of particle size of corn starch	67
3.6	Half-normal plot (I) and Pareto chart (II) indicating the critical factors for the zeta potential of corn starch	68
3.7	One factor plot showing the effect of the volume of DMSO on the zeta potential of corn starch	69
3.8	Half-normal plot (I) and Pareto chart (II) indicating the critical factors for particle yield of corn starch	69
3.9	One factor indicating the effect of surfactant on the yield corn starch	70

Figure		Page
3.10	Interaction plot showing combined effect of starch content and DMSO on yield of corn starch	70
3.11	A simplified illustration showing drying mechanism for droplet drying and the types of different particles as outputs	77
4.1	Working of High Intensity Sonic Vibra Cell Probe Sonicator [®] , Autotune series (Sonic and Materials Inc., USA)	79
4.2	Peaks showing size distribution of particles as monomodal (I), skewed (II), skewed and bi-modal (III) and multi modal (IV)	85
4.3	Effect of pulsed ultrasonication on the particle size of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	87
4.4	Effect of pulsed ultrasonication on the polydispersity index (PDI) of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	88
4.5	Effect of continuous ultrasonication on the particle size of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	89
4.6	Effect of continuous ultrasonication on the polydispersity index (PDI) of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	89
4.7	Effect of different concentrations of phospholipid on the particle size of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	91
4.8	Effect of different concentrations of phospholipid on the polydispersity index (PDI) of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	91
4.9	Effect of different surfactants on the particle size of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	93
4.10	Effect of different surfactants on the polydispersity index (PDI) of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	93
4.11	Effect of trehalose and glucose on the particle size (I), polydispersity index (PDI) (II) and zeta charge (III) of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	95
4.12	Effect of the types of starch on the particle size	98
4.13	Perturbation plot showing the relative effect of factors on particle size of potato starch (I), soluble starch (II) and corn starch (III)	98
4.14	Counter and response surface plots showing the effect of homogenisation time and ultrasonication amplitude on the particle size of potato starch (I-II), soluble starch (III-IV) and corn starch (V-VI)	99
4.15	Counter and response surface plots showing the effect of homogenisation speed and ultrasonication amplitude on the particle size of potato starch (I-II), soluble starch (III –IV) and corn starch (V-VI)	101
4.16	Interaction plots showing combined effect of starch type and each of homogenisation time (I) and homogenisation speed (II) on particle size of potato starch, soluble starch and corn starch	102

Figure		Page
4.17	Perturbation plots showing the relative effect of factors on polydispersity index (PDI) of potato starch (I), soluble starch (II) and corn starch (III)	103
4.18	Effect of types starch on the polydispersity index (PDI) of potato starch, soluble starch and corn starch	103
4.19	Response surface plots showing the effect of homogenisation speed and homogenisation time on polydispersity index (PDI) of potato starch (I), soluble starch (II) and corn starch (III) and of homogenisation time and ultrasonication amplitude on PDI of potato starch (IV), soluble starch (V) and corn starch (VI)	104
4.20	Interaction plots showing combined effect of types of starch and each of homogenisation time, speed and ultrasonication amplitude on polydispersity index (PDI) of potato starch (I), soluble starch (II) and corn starch (III)	105
4.21	Effect of starch type on the zeta potential of potato starch, soluble starch and corn starch	106
4.22	Mechanism of size reduction by ultrasonication	115
5.1	Mechanism of size reduction (I) Schematic illustration (II) and Photograph (III) of Netzsch MiniCer [®] laboratory circulation machine	118
5.2	Effect of milling time on the particle size and polydispersity index (PDI) of potato starch, soluble starch and corn starch Mean \pm SD, N = 3.	126
5.3	Effect of heating on the particle size and polydispersity index (PDI) of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	127
5.4	Effect of Pluronic-F68 on the particle size and polydispersity index (PDI) of potato starch, soluble starch and corn starch. Mean \pm SD, N = 3.	128
5.5	Effect of different surfactants and milling time on the particle size of potato starch (PS), soluble starch (SS) and corn starch (CS). Mean \pm SD, N = 3.	129
5.6	Effect of different surfactants on the polydispersity (PDI) index of potato starch (PS), soluble starch (SS) and corn starch (CS). Mean \pm SD, N = 3.	130
5.7	Three-D surface plot of starch type and surfactants for particle size and polydispersity index (PDI) at the mid levels of milling time and surfactant concentration	131
5.8	Effect of cross-linking reaction time and milling time on the particle size and polydispersity index (PDI) of potato starch (PS), soluble starch (SS) and corn starch (CS). Mean \pm SD, N = 3.	132
5.9	Effect of the size of grinding media on the particle size of potato starch (PS), soluble starch (SS) and corn starch (CS). Mean \pm SD, N = 3.	133

Figure		Page
5.10	Effect of amylase on the particle size and polydispersity index (PDI) of potato starch (PS), soluble starch (SS) and corn starch (CS). Mean \pm SD, N = 3.	134
5.11	Effect of starch contents on the particle size and polydispersity index (PDI) of potato starch (PS), soluble starch (SS) and corn starch (CS). Mean \pm SD, N = 3.	135
5.12	Effect of pH on the particle size and polydispersity index (PDI) of potato starch (PS), soluble starch (SS) and corn starch (CS). Mean \pm SD, N = 3.	136
5.13	Effect of omission of glycerol on the particle size and polydispersity index (PDI) of potato starch (PS), soluble starch (SS) and corn starch (CS). Mean \pm SD, N = 3.	137
5.14	Effect of addition of PEG on the particle size and polydispersity index (PDI) of potato starch (PS), soluble starch (SS) and corn starch (CS). Mean \pm SD, N = 3.	138
5.15	Effect of different surfactants and their concentrations on the particle size of potato starch (PS), soluble starch (SS) and corn starch (CS). Mean \pm SD, N = 3.	139
5.16	Effect of different surfactants and their concentrations on polydispersity index of potato starch (PS), soluble starch (SS) and corn starch (CS). Mean \pm SD, N = 3.	140
6.1	Half-normal (I) and Pareto chart (II) showing effects of 7 variables on particle size of potato starch	161
6.2	Interaction plot showing combined effect of citric acid and surfactant on particle size of potato starch	161
6.3	Perturbation plot showing the relative effect of factors on the particle size	162
6.4	Response surface plot showing the effect of surfactant and citric acid on the particle size of potato starch when all other parameters are set at their mid levels	162
6.5	Cube plot showing combined effect of citric acid, surfactant and speed together	163
6.6	Half-normal plot (I) and Pareto chart (II) indicating critical factors for polydispersity index of potato starch	163
6.7	The perturbation plot showing the relative effect of factors on the polydispersity index (PDI) of potato starch nanoparticles	164
6.8	Response surface plot for the effect of phospholipid and glycerol (I), speed and glycerol (II) and surfactant and speed (III) on the polydispersity index of potato starch	165
6.9	Cube plot, showing simultaneously effect of three parameters, phospholipid, glycerol and surfactant concentration (I) and glycerol, surfactant and speed (II) on the polydispersity index of potato starch	165
6.10	Half-normal plot (I) and Pareto chart (II) indicating critical factors for zeta potential of potato starch	166

Figure		Page
6.11	The perturbation plot showing the relative effect of factors on the zeta potential of potato starch nanoparticles	167
6.12	Response surfaces, respectively for the effect of D and F (I), D and E (II), A and G (III) and A and E (IV) on zeta potential of potato starch	168
6.13	Cube plot showing effect of glycerol, citric acid and surfactant concentration (I) and citric acid, grinding time and speed (II) on zeta potential of potato starch	168
6.14	Effect of increasing concentration of citric acid (I) and processing time (II) on the particle size of potato starch	171
6.15	Perturbation plot showing the relative effect of factors on polydispersity index (PDI) of potato starch	171
6.16	Response surfaces, respectively for the effect of glycerol and phospholipid (I-II), glycerol and speed (III-IV), phospholipid and processing time (V-VI) and citric acid and surfactant (VII-VIII) on the PDI of potato starch	172
6.17	Perturbation plot showing the relative effect of factors on zeta potential of potato starch	173
6.18	One factor plot (I to III) and cube plot (IV) showing the individual effect of glycerol (I), citric acid (II), surfactant concentration (III) and milling speed and collectively (IV) on the polydispersity index of potato starch	174
7.1	Side-by-side diffusion cells, clamped (left) and unclamped (right)	190
7.2	Particle yield (%) and drug loading efficiency (%) of starch particulate formulations. Mean \pm SD, N = 4.	193
7.3	Particle size of the blank and drug loaded potato starch particulates. Mean \pm SD, N = 4.	196
7.4	Polydispersity index of the blank and drug loaded potato starch particulates. Mean \pm SD, N = 4.	196
7.5	Zeta potential of the blank and drug loaded potato starch particulates. Mean \pm SD, N = 4.	197
7.6	Particle size of the blank and drug loaded soluble starch particulates. Mean \pm SD, N = 4.	197
7.7	Polydispersity index of the blank and drug loaded soluble starch particulates. Mean \pm SD, N = 4.	198
7.8	Zeta potential of the blank and drug loaded soluble starch particulates. Mean \pm SD, N = 4.	199
7.9	Average drug release (%) for free drug and the starch particulates in phosphate buffer, pH 5.5. Mean \pm SD, N = 6.	199
8.1	Experimental design for the controls and starch micro- and nanoparticles	208

Figure		Page
8.2	Plasma concentrations of cefotaxime sodium after single oral administration as free drug (C_{AQUEOUS}), potato starch vehicle ($C_{\text{VEHICLE-PS}}$) and loaded with cross- and uncross-linked potato starch particulates ($F_{\text{PS-CL}}$ and $F_{\text{PS-UCL}}$, respectively) to male Sprague-Dawley rats. Mean \pm SD, N = 6. (The lower error bar has been removed from the last two points of C_{AQUEOUS})	213
8.3	Plasma concentrations of cefotaxime sodium after single oral administration as free drug (C_{AQUEOUS}) and soluble starch vehicle ($C_{\text{VEHICLE-SS}}$) and loaded with cationic, anionic and neutral soluble starch particulates ($F_{\text{SS-UCL}}^+$, $F_{\text{SS-UCL}}^-$ and $F_{\text{SS-UCL}}^0$, respectively) to male Sprague-Dawley rats. Mean \pm SD, N = 6. (The lower error bar has been removed from the last two points of C_{AQUEOUS})	214
8.4	Plasma concentrations of cefotaxime sodium after single oral administration as free drug (C_{AQUEOUS}) and as drug loaded spray-dried corn starch particulates ($F_{\text{CS-SPD}}$) to male Sprague-Dawley rats. Mean \pm SD, N = 6. (The lower error bar has been removed)	214
8.5	Plasma concentrations of cefotaxime sodium after single oral administration as loaded uncross-linked potato starch ($F_{\text{PS-UCL}}$), soluble starch ($F_{\text{SS-UCL}}^+$) and spray-dried corn starch particulates ($F_{\text{CS-SPD}}$) to male Sprague-Dawley rats. Mean \pm SD, N = 6)	215
8.6	Illustration to propose release of drug from starch particulates by swelling of starch in the presence of water and subsequent digestion	231

LIST OF PLATES

Plate		Page
3.1	Plate 3.1: Starch particles by using DMSO in PVA 0.1 % aqueous solution (I), in water containing acacia 0.5 % and magnetic stirring at 40°C (II), in trichloroethylene added in ethyl acetate (III) and in DMSO added in hot water (IV)	72
7.1	Scanning electron micrographs of potato starch, soluble starch and corn starch	194

LIST OF SYMBOLS

Symbol	Description
∞	Infinity
μ	micro
σ	standard deviation of intercept

LIST OF ABBREVIATIONS

Abbreviation	Description
Adeq Pre	adequate precision
Adj R ²	adjusted correlation coefficient
ANN	artificial neural network
ANOVA	analysis of variance
AOT	aerosol OT (1,4-bis(2-ethylhexyl) sodium sulfosuccinate)
ATR-AOT	combination of surfactants AOT and ATR
ATR	aerosol TR (sodium 1,2-bis (tridecoxycarbonyl) ethanesulfonate)
AUC _{0-∞}	area under the curve from zero to infinity
AUC _{0-∞, norm}	dose and weight normalised area under the curve
AUC _{0-t}	area under the curve from zero to time t
AUFS	absorbance units full scale
BBD	box Behnken Design
BCS	biopharmaceutical classification system
BOS	based on starch
°C	Degree Celsius
C _{AQUEOUS}	control containing cefotaxime sodium in aqueous solution
CCD	central composite design
CI	confidence interval
C _{max}	peak concentration
C _{max, norm}	dose and weight normalised peak concentration
CS	corn starch
CTAB	cetyl trimethyl ammonium bromide
C _{VEHICLE-PS}	control containing vehicle for potato starch
C _{VEHICLE-SS}	control containing vehicle for soluble starch
CYP 450	cytochrome P 450
DDS	drug delivery system
DMSO	dimethyl sulfoxide
DoE	Design of experiment
DX [®]	Design Expert [®]
EDTA	ethyl diamine tetra acetate
FCD	face-centre composite design

Abbreviation	Description
F_{CS-SPD}	microparticles of cross-linked, spray-dried corn starch
FDA	food and drug regulation authority
FEG-ESEM	field-emission gun environmental scanning electron microscopy
FI	factor interaction
F_{PS-CL}	nanoparticles of cross-linked potato starch
F_{PS-UCL}	nanoparticles of uncross-linked potato starch
F_{SS-UCL}^{-}	nanoparticles of uncross-linked anionic soluble starch
F_{SS-UCL}^{+}	nanoparticles of uncross-linked cationic soluble starch
F_{SS-UCL}^{0}	nanoparticles of uncross-linked neutral soluble starch
<i>F</i> value	Fisher's statistics value
g/mol	gram per mole
GIT	gastro intestinal tract
HLB	hydrophilic-lipophilic balance
HPLC	high performance liquid chromatography
Hr	hour
Hz	hertz
ICH	International committee on harmonisation
K_{elim}	elimination rate constant
Kg	Kilogram
kPA	kilopascal
LOD	Limit of detection
LOQ	Limit of quantification
M	molar
M-cells	modified epithelial cells
MDT	mean dissolution time
mg	milligram
min.	minute
ml	millilitre
mm	Millimetre
MRPs	Multidrug resistance proteins
mV	milli electron volt

Abbreviation	Description
MW	molecular weight
n	release exponent
N	normal; number of replicate/samples
nER	number of experimental runs
nF	number of factors
nL	number of levels of the factors
nm	nanometre
O/W	oil in water
OFAT	one factor at a time
p	probability
PAS	publicly available standard
PDI	polydispersity index
PE	processing element
PEG	polyethylene glycol
P-gp	p-glycoprotein
pH	power of hydrogen ion concentration
PI	prediction index
Pred R ²	predicted coefficient of correlation
PS	Potato starch
PSA	polar surface area
R ²	correlation coefficient
RES	reticuloendothelial system
RPM	revolution per minute
RSD	relative standard deviation
RSM	response surface methodology
SEM	scanning electron microscopy
SLNs	solid lipid nanoparticles
SS	soluble starch
T _g	transition temperature
T _{max}	time for peak concentration
VIF	variation inflation factor
v/v	volume per volume
W	Watt
W/O/W	water in oil in water
w/w	weight by weight

MENGAJI POTENSI ZARAH KANJI TEROPTIMUM SEBAGAI PELANTAR UNTUK PENYAMPAIAN ORAL SATU MODEL DRUG GASTROLABILE SEFOTAKSIM NATRIUM

ABSTRAK

Penggunaan zarah adalah pendekatan utama untuk sistem penghantaran kejuruteraan bagi mengatasi rintangan-rintangan di gastrousus. Kanji mempunyai ciri-ciri yang sesuai diperlukan sebagai satu zarah bahan pembuatan. Kanji mudah dibioteruraikan, selamat, murah dan banyak walaupun bagaimanapun, kurang digunakan sebagai bahan penyediaan, berbanding biopolymer yang lain. Kerja ini melaporkan kaedah-kaedah yang mudah dan berinovasi termasuk pengeringan sembur, ultrasonikasi dan pengisaran nano untuk produksi saiz micron dan submicron zarah kanji. Zarah kanji teroptimum direka melalui kaedah pemprosesan dan formulasi menggunakan algoritma dengan bantuan komputer.

Ultrasonifikasi gagal menghasilkan zarah kanji secara berulang dengan menggunakan bantuan pemprosesan. Pengeringan sembur menghasilkan partikel dengan saiz $21.64 \pm 1.36 \mu\text{m}$ (keseragaman 0.56 ± 0.135) bagi kanji jagung. Kaedah pengisaran nano kelihatan menjanjikan untuk penghasilan partikel submikron secara berulang dengan kawalan mengenai ciri-ciri zarah melalui modulasi parameter proses dan formulatif. Kanji kentang menghasilkan partikel bersilang dengan saiz dan indeks serakan berganda (PDI) masing-masing 200 nm dan 0.25. Potensi zeta untuk kanji kentang adalah $> -21 \text{ mV}$. Kanji terlarutkan yang tidak bersilang menghasilkan partikel yang bersifat kation, anion dan neutral dengan potensi masing-masing $+8.59 \pm 0.45$, -10.5 ± 0.20 dan $2.00 \pm 0.30 \text{ mV}$, saiz partikel tersebut $< 200 \text{ nm}$ dan $\text{PDI} < 0.25$. Kanji jagung pula menghasilkan partikel tidak bersilang dengan saiz sekitar 500 nm dengan $\text{PDI} > 0.40$, iaitu satu nilai yang sedikit tinggi daripada nilai PDI yang boleh diterima, oleh itu partikel kanji jagung tidak dioptimumkan. Persilangan kanji kentang dan jagung berciri hidrofobik.

Semburan kering kanji jagung, pengisaran nano silang- dan tidak bersilang kanji kentang dan beranion, kation dan neutral kanji terlarut dipilih untuk kajian *in vitro* dan *in vivo*. Kentang dan kanji terlarut menunjukkan keberkesanan muatan > 9.55%. Kanji jagung menunjukkan keberkesanan muatan yang rendah iaitu 2.30%, mungkin disebabkan hasil rendah kanji jagung ($27.77 \pm 1.48\%$) berbanding kanji kentang dan kanji jagung (> 84%). Pertumbuhan saiz zarah telah diperhatikan selepas tempoh waktu tertentu, dalam zarah kanji terlarut. Pembebasan *in vitro* zarah mematuhi model tertib sifar dengan eksponen resapan <1, menggambarkan sifat pembebasan oleh resapan bengkok. Perbandingan bagi sefotaksim natrium bebas, kanji kentang tidak bersilang dan kanji terlarut kation menunjukkan 4.82 dan 2.59 lipatan peningkatan dalam ketersediaan biohayati, masing-masing. Oleh itu, kanji mungkin mempunyai potensi bagi menyampaikan gastrolabile drug, sefotaksim natrium dan dengan itu, untuk meningkatkan keterbiosediaan oral.

Sebagai kesimpulan, partikel kanji bersaiz mikron dan submikron yang teroptimumkan boleh disediakan menggunakan kaedah fizikal melalui gabungan sains farmaseutikal dengan kaedah pengoptimuman dengan bantuan komputer. Zarah adalah mampu untuk meningkatkan keterbiosediaan sefotaksim natrium. Walaubagaimanapun, kestabilan fizikal zarah perlu terus untuk diperbaiki.

EXPLORING THE POTENTIAL OF OPTIMISED STARCH PARTICULATES AS PLATFORM FOR ORAL DELIVERY OF A MODEL GASTROLABILE DRUG CEFOTAXIME SODIUM

ABSTRACT

Use of particulates is a prominent approach for engineering delivery systems to overcome gastrointestinal barriers. Starch has desired properties necessary for a particulate fabrication material. It is biodegradable, safe, cheap and abundant however, has attracted less research attention, comparative to other biopolymers. This work reports simple and innovative top-down physical methods including spray-drying, ultrasonication and nanomilling for production of micron and submicron size starch particles. The optimised starch particulates were fabricated with use of processing and formulative aids employing computer-aided algorithm.

Ultrasonication was unsuccessful in generating reproducible starch particles with processing aids used. Spray-drying produced particle size of $21.64 \pm 1.36 \mu\text{m}$ (dispersion in uniformity of particle size 0.56 ± 0.135) for corn starch. Nanomilling seemed promising for production of reproducible submicron particles with control over particle characteristics by modulation of process and formulative parameters. Potato starch produced cross-linked particles with size and polydispersity (PDI) of 200 nm and 0.25, respectively. The zeta potential of potato starch was $> -21 \text{ mV}$. Uncross-linked soluble starch yielded cationic, anionic and neutral particles with charges $+8.59 \pm 0.45$, -10.50 ± 0.20 and $2.00 \pm 0.30 \text{ mV}$, respectively with particle size $< 200 \text{ nm}$ and $\text{PDI} < 0.25$. Corn starch uncross-linked particle size was around 500 nm with $\text{PDI} > 0.40$ which was slightly higher than generally accepted PDI values, thus corn starch particles were not optimised. Cross-linked potato and corn starch were somewhat hydrophobic.

The spray-dried corn starch, nanomilled cross- and uncross-linked potato starch and anionic, cationic and neutral soluble starch were selected for *in vitro* and *in vivo* studies.

Potato and soluble starch demonstrated loading efficiency > 9.55 %. Corn starch showed low loading efficiency of 2.30 %, probably due to its lower yield (27.77 ± 1.48 %) as compared to that of potato and corn starch (> 84 %). Particle size growth was observed over time prominently, in soluble starch particulates. The *in vitro* release of particulates followed zero order model with diffusion exponent < 1, characterising release by swelling-diffusion. Comparative to free cefotaxime sodium, the uncross-linked potato starch and cationic soluble starch showed 5.28 and 3.11 folds increase in bioavailability, respectively. Thus, starch may have potential to deliver gastrolabile drug, cefotaxime sodium and thereby, to enhance its oral bioavailability.

In conclusion, the micron and submicron size optimised starch particles can be prepared using physical methods by blending pharmaceutical science with computer-aided optimisation. The particulates are capable to enhance bioavailability of cefotaxime sodium. However, physical stability of particulates is needed to be improved further.

CHAPTER 1

GENERAL INTRODUCTION AND AIMS OF STUDY

1.1 THE ORAL ROUTE OF ADMINISTRATION

Among the routes of drug administration, per oral administration is the most dominant, convenient and preferred portal by which drugs are presented for systemic effects (Davenport, 1982; Lee and Yang, 2001). It is relatively safe and affords high acceptability, convenience and maximum compliance, in combination with the relative low cost, simple and cost-efficient manufacturing process (Lee and Yang, 2001). Nevertheless, the route is not without limitations, which prohibit the accomplishment of the full benefits of the route (Mahato *et al.*, 2003). Substantial number of existing and new pharmaceuticals moieties exhibits poor oral absorption (Amidon *et al.*, 1995; Hoerter and Dressman, 1997; Devane, 1998). Despite of the above limitation, the design of an oral dosage form is usually the first choice for the new medicinal entities and aims to reformulate and/or optimise dosage forms of the existing drugs. The objective of the current oral formulation design is to develop a dosage form capable of absorption into blood in right time and amount after administration (Macheras *et al.*, 1995). The drug absorption after oral administration is a complex process, requiring series of events (Ungell, 1997).

1.1.1 Drug absorption after oral route of administration

The small intestine usually is the most favourable site for drug absorption due to its large surface area endowed by microvilli and, therefore, delivery of drug to this region is usually a prerequisite for absorption (Davis *et al.*, 1986). The microvilli consist of loose connective tissue and are supplied with blood and lymphatic system at their base (DeMarco and Levine, 1969). If absorbed into blood stream, the drug passes through the liver before its entry into the systemic circulation. However, the drug taken up by lymph accesses the systemic circulation without passing through liver (O'Driscoll, 1992; Ungell, 1997; Martinez and Amidon, 2002). Drug absorption after oral administration depends on physicochemical, pharmaceutical and physiological factors and on the efficiency with which a drug crosses the

several barriers prior to reaching into the systemic circulation (Kinget *et al.*, 1998; Ashford, 2002a; Ashford, 2002b; Mahato *et al.*, 2003; Barrett, 2004). In line with the scope of the present study, only the physiological factors will be discussed under barriers to drug absorption after oral administration (Section 1.1.2).

1.1.2 Barriers to drug absorption after oral administration

GIT provides a variety of morphological (spatial) and physiological (functional) barriers to the arrival of a drug to systemic circulation (Ashford, 2002b). Morphological barriers are mucus and epithelial and endothelial cells while the physiological factors are pH, enzymes, presystemic biotransformation, enterohepatic circulation and counter absorption mechanisms (Shargel *et al.*, 2004). The above barriers are given in Figure 1.1.




Figure 1.1: Morphological and functional barriers for drug absorption after oral administration

1.1.2(a) Gastrointestinal tract milieu

The pH, enzymes, secretions and foods in gastrointestinal tract (GIT), together make the GIT milieu. The pH varies along the length of GIT, from very slightly acidic mouth region to very acidic region of stomach followed by another change to the neutral pH in the proximal small intestine (Davenport, 1982). Thus, the drug is exposed to fluctuating pH

while it passes along the GIT. The GIT pH influences or completely halts the absorption of drugs by affecting their chemical stability and ionisation or by acid- or base-mediated drug inactivation (Lee and Yang, 2001). Pepsin is the primary enzyme in the stomach while lipase, amylases and proteases are secreted from pancreas into the small intestine (Davenport, 1982). Drugs, particularly peptides, nucleotides and fatty acids are susceptible to enzymatic degradation (Lee, 1991; Wilson and Washington, 2001). The presence of food interferes with the drug absorption by retarding the gastric emptying time, provision of viscous environment and/or provoking the enzyme and acid secretions (Toothaker and Welling, 1980; Lee and Yang, 2001).

1.1.2(b) Mucus

Mucus on the lining of GIT epithelial cells is secreted by the mucosal cells of GIT epithelia. It consists of glycoprotein and glycocalyx (sulphated mucopolysaccharides) and is hydrophilic which is attributed to 95 % of water it contains (Csaky, 1984). Its most important property is the viscoelasticity, enabling it to act as a physical diffusion barrier for drug or to make complexes to some drugs thus, leading to impaired absorption (Gu *et al.*, 1988; Norris *et al.*, 1998; Ashford, 2002b).

1.1.2(c) Epithelial cells – the mechanical barrier on the lumen side

The small intestine is lined with a single layer of tightly joined columnar epithelial cells, called enterocytes (Squier, 1992; Lennernas, 1998). Higher molecular weight, lack of lipophilicity, presence of charge or epithelial binding prohibits translocation of certain drugs across intestinal epithelium (Gu *et al.*, 1988; Tenhoor and Dressman, 1992; Squier, 1992; Amidon *et al.*, 1995; Hoerter and Dressman, 1997).

1.1.2(d) Epithelial permeation, transport pathways and mechanisms

The uptake pathways, permeation mechanisms, transporters and efflux pumps have been regarded as biophysical and biochemical barriers. In the intestinal epithelium, the

possible mechanisms for the permeation of drugs are passive diffusion, carrier-mediated and endocytosis through the paracellular and transcellular pathways (Squier, 1992; Tsuji and Tamai, 1996). Paracellular drug flux is limited to small molecules and is of limited relevance in the most cases (Carino and Mathiowitz, 1999). The transcellular route is available for diffusion of small lipophilic molecules. The hydrophilic compounds are transported by carrier-mediated transport or by endocytosis (Carino and Mathiowitz, 1999; Ashford, 2002b).

In endocytosis, the particles are internalised by phagocytosis or pinocytosis and this occurs at specialised regions of membrane. Thus, drug absorption depends upon the region where they are present (Russell-Jones, 2004; Belting *et al.*, 2005). After internalisation, the molecule may be acted upon by a range of destructive processes or substances including proteases and nucleases or is extruded out by efflux pumps. Distribution, affinity, capacity, specificity and direction of epithelial transporters and pumps play an important role in drug absorption (Ayrton and Morgan, 2001; Steffansen *et al.*, 2004). Absorption of the following drugs is particularly affected; a) drugs having affinity to the intestinal transporters and b) drugs for which the passive diffusion is of no relevance due to higher molecular weight or low partition coefficient (Tsuji and Tamai, 1996; Ayrton and Morgan, 2001; Daniel, 2004; Steffansen *et al.*, 2004).

1.1.2(e) Efflux transporters and pumps

The epithelial or endothelial permeability of a drug depends on the membrane carriers, known as “efflux transporters” which recognize substrate drugs and restrict their transport. The most documented efflux transporters belong to ATP-binding cassette, super family of transporters, including P-glycoprotein (P-gp) and multidrug resistance proteins (MRPs) (Kleinzeller, 1999; Westpahal *et al.*, 2000; Walgren *et al.*, 2000). The P-gp acts as a barrier by preventing drugs from crossing GIT epithelium into blood or extruding them from blood into bile. The transporters include a broad structural diversity of substrates and thus,

affect several therapeutic classes (Leonard *et al.*, 2002; Chan *et al.*, 2004). The MRPs confer resistance to substrate lipophilic anions. Many structurally diverse drugs are the substrates for MRPs (Borst *et al.*, 1999; Bakos *et al.*, 2000; Miller, 2001; Kim, 2003; Kruh and Belinsky, 2003).

1.1.2(f) Endothelial cells – the mechanical barriers on apical side

The endothelium, a cellular lining of the blood vessels underlying the GIT mucosa has fenestrations with pores of 80-100 nm size that allow paracellular transport. However, the presence of P-gp efflux in endothelium is highly restrictive for the transport of drugs using the transcellular route (Firth, 2002; Feng *et al.*, 2002).

1.1.2(g) Presystemic cellular metabolism

The enterocytes contain phase I drug metabolizing enzymes, dominantly Cytochrome P450 (Wacher *et al.*, 1996; Watkins, 1997) and hydrolytic and phase II drug metabolizing enzyme such as, acetyltransferases and sulfotransferases (Krishna and Klotz, 1994; Wacher *et al.*, 1998). The substrate drugs for the Cytochrome P450 (CYP450) enzyme undergo extensive metabolism after uptake in the intestinal wall (Kolars *et al.*, 1991; Wacher *et al.*, 1996; Benet *et al.*, 1996; Wacher *et al.*, 1998). The co-localisation of efflux transporters and metabolizing enzymes in the enterocytes, together with the substantial overlap in their substrate specificity, seems to indicate the existence of interplay between drug transporters and metabolizing enzymes suspected to synergize recycling of the substrate over the apical membrane. This increases the exposure of substrate drugs to the metabolizing enzymes (Cummins *et al.*, 2002; Benet *et al.*, 2004; Chan *et al.*, 2004).

1.1.2(h) Presystemic hepatic metabolism

The heptoportal blood exposes the drugs to liver on its way to systemic circulation and the substrate drugs are extensively metabolised via oxidation by CYP450 enzyme or phase II reactions arising from conjugation with glutathione, sulphate or glucuronic acid.

Only CYP3A4, a predominant member of the CYP450 mixed-function oxidase enzyme, metabolizes 50 % of all the drugs currently prescribed (Evans and Relling, 1999; Clarke and Jones, 2002). Thus, liver extraction and thereby premetabolism substantially reduces the systemic availability of susceptible drugs (Arimori and Nakano, 1998).

1.1.2(i) Enterohepatic shunt

The enterohepatic shunt is a cycle of events after drug absorption from intestine, where a drug secreted into the bile is presented to the intestine for absorption again and then secretion into bile. This cycle entails the increased persistence of drug in the body or inactivation of drug (Shargel *et al.*, 2004).

1.2 STRATEGIES TO OVERCOME BARRIERS FOR ORAL DELIVERY

To be able to permeate through intestinal membrane, a drug must have following biopharmaceutical properties; ability to withstand the insults with appropriate stability in the hostile GIT environment, appropriate hydrophilicity to dissolve in the gastric fluids and sufficiently lipophilic to permeate through the cellular barrier (Thompson, 1997). Furthermore, it should not be a substrate for presystemic cellular or hepatic inactivation of efflux pumps (Ashford, 2002b). Several strategies have been proposed to generate or enhance the above biopharmaceutical features in the dosage form for oral delivery. Among many absorption barriers, the gastric liability has been addressed as one of the most important barriers in drug absorption (Amidon *et al.*, 1995; Hoerter and Dressman, 1997; Macheras and Iliadis, 2005). In line with the scope of the present work, only the strategies to overcome insufficient gastric stability will be discussed.

1.2.1 Approaches addressing gastric liability

The drugs with adverse biopharmaceutical properties are usually delivered through parenteral route or are enteric-coated (Moes, 1993; Hillery *et al.*, 2001). The parenteral route is invasive, usually with brief effects and impossible to terminate drug action, if required

(Robinson and Lee, 1987; Evers, 1997). The enteric coatings contain indigestible solids and make product often of considerable size, prohibitive for patients with gastric hypomotility or pyloric channel narrowing. The location where an enteric coating starts dissolving is uncertain and release may occur within the small intestine or deep in the colon. The large inter- and intra-patient variations leads to a varied drug release (Lee and Yang, 2001). To avoid the above limitations the recent research has been directed towards the use of convenient alternatives to parenteral route, such as sublingual, pulmonary and vaginal route for gastric liable drugs (MacGregor and Graziani, 1997) and preferably, to develop successful oral delivery systems (Lee, 1991; Zhou, 1994; Hillery *et al.*, 2001).

1.2.1(a) Chemical modification – prodrug and drug analogue

A drug can be made enzymatically stable by presenting it as a prodrug with the substitution of chemical group(s) in the drug molecule (Vilhardt, 1990; Lloyd and Smith, 1998). Recently PEGylation, a chemical modification approach using conjugation or cross-linking of drug with polyethylene glycol (PEG) has gained significant interest (Hinds, 2005). The approach prevents the degradation of PEGylated drug from proteolytic enzymes, reduces drug clearance rate and offers a shield to uptake by the reticuloendothelial system (RES) (Roberts *et al.*, 2002). Nevertheless, prodrug strategy might not be adequate because a prodrug is considered as new chemical entity, thus requires the preclinical and clinical investigations. Therefore, approaches involving the change of formulation or engineering of the drug absorption are feasible (Hillery *et al.*, 2001).

1.2.1(b) Lipidisation strategies

Lipidisation involves the formation of drug in appropriate pre-solubilised lipid phase, which by the metabolism of the lipids in GIT facilitates drug absorption (Humberstone and Charman, 1997). It may be achieved by incorporation of drug into lipid vehicle such as oils, surfactants, dispersions, micelles of mixed bile salt, liposomes, or emulsifying systems (Gershanik and Benita, 2000; Frokjaer *et al.*, 2005). Such systems have

reported to improve bioavailability due to impeded gastric emptying time, increased permeability and facilitated lymphatic uptake mediated by special carriers, chylomicrons and very low density lipoproteins in epithelial cells (Sernka *et al.*, 1979; Schilling and Mitra, 1990; Macheras *et al.*, 1995).

1.2.1(c) Polymeric coating, encapsulation or entrapment

Coating with, encapsulation and entrapment of drug in polymer is used to protect the gastric labile drugs. Depending upon polymeric materials used, they may form coating film, hydrogels and matrices (Graham and McNeil, 1984; Kopecek *et al.*, 1992; Brondsted and Kopeck, 1992). Several pH-dependent polymeric materials are available which are stable at acidic pH and dissolve in the intestinal or colonic pH. Thus, coating with such polymer protects the gastric unstable drugs (Touitou and Rubinstein, 1986; Saffran, 1991). Hydrogels are the cross-linked hydrophilic polymers able to swell in aqueous environment. This swellability is controllable by pH, degree of cross-linking and temperature. Hydrogels encapsulated drugs can be targeted to specific pH and thus, are attractive as drug delivery systems able to protect drugs at acidic pH (Frokjaer *et al.*, 2005).

1.2.1(d) Drug targeting to the lymphatics

Oral route has proven feasible for the lymphatic uptake of lipophilic drugs and their subsequent access to the systemic circulation without passing through liver. The total flow rate of the lymph in the thoracic duct is approximately 100-200 ml/hr, 500 times less than the blood flow in portal vein (O'Driscoll, 1992; Porter and Charman, 2001). Thus, the lymph portal may be used to achieve sustained drug release and to avoid first pass metabolism. The endothelial layer of lymphatic capillaries is discontinuous or without basement membrane thus, allowing a free permeation, independent of the molecular size (Hastewell *et al.*, 1991).

A drug with molecular weight greater than 16,000 reaches systemic circulation through the lymph (Porter and Charman, 2001; Swartz, 2001; Feng *et al.*, 2002). Delivery

systems can selectively redirect drug absorption into the lymphatics. Drugs in lipid-based particles or oil enhances lymphatic uptake, while macromolecules and colloidal particles, after endocytosis or persorption (Figure 1.2) may enter the lymphatic system through clefts in the terminal vessels (Muranishi, 1997; Nishioka and Yoshino, 2001; Wassan, 2002).

1.2.1(e) Drug targeting to the Peyer's patches

Peyer's patches, concentrated in the ileum are the collection of large lymph tissues in the intestinal mucus-secreting lining and appear as the elongated thickened areas lacking villi (Figure 1.2). The patches are associated with the immune system and contain large number of lymphocytes. Specialised antigen-presenting epithelial cells, called modified epithelia (M) cells cover the patches. Features of M-cells, important in connection with drug absorption can be discriminated from that of the enterocytes. The M-cells have apical microfolds and lack or if have, under-developed microvilli and the mucus covering is assumed to be attenuated to allow antigenic uptake perhaps by adsorptive and/or receptor-mediated process. Thus, M-cells are capable of relatively extensive macromolecular endocytosis (Eldridge *et al.*, 1990; Walgren *et al.*, 2000). The phagocytotic potential of lymphocytes provides a concentration gradient for drug permeation.




Figure 1.2: Microvilli showing epithelial cells and underneath two circulatory systems, blood and lymphatic stream. A special transport mechanism, persorption is also shown

Targeting the Peyer's patches helps an enhanced drug uptake into lymphatics that depends on particles size, surface hydrophobicity and availability of specific targeting ligands (Eldridge *et al.*, 1990; Muranishi and Yamamoto, 1994). Particle with size range of 50-3,000 nm are taken up by the Peyer's patches and through the lymphatics, subsequently translocated to blood. The particles of size 0.5–1.0 μm are phagocytised by lymphocytes, which migrate to the draining lymph nodes (Jani *et al.*, 1992; Randolph *et al.*, 1999; Jung *et al.*, 2000). The particles of size 3-10 μm are often retained within the Peyer's patches. Particles of size 2-3 μm exhibit the maximal phagocytosis (Champion *et al.*, 2008). A higher uptake is generally observed for more hydrophobic microparticles. Monoclonal antibodies which bind to the specific M-cells-bound carbohydrate residues may increase microparticulates uptake (Eldridge *et al.*, 1990).

1.2.1(f) Targeted drug delivery to the colon

A couple of strategies have been explored for targeting drug to the colon. One of the colonic drug delivery strategies is based on the design of a prodrug which is metabolised by enzymes found exclusively in the colon (Lee and Yang, 2001; Chourasia and Jain, 2003). Azoreduction of polymeric coating is a further important approach used for targeted drug delivery to the colon. The colonic anaerobic bacteria reductively cleave azo bonds leading to the disruption of the polymer network in the coating to release drugs (Van Den-Mooter *et al.*, 1992). Coating of azo polymeric systems onto pellets and solid unit dosage forms is another novel approach and shown to promote the oral administration of insulin and desmopressin (Saffran, 1991; Kopecek *et al.*, 1992).

Hydrogels are reported to have excellent persistence properties in the lower part of the rectum and hence demonstrate a potential of enhancing the colonic absorption of drugs (Graham and McNeil, 1984; Brondsted and Kopecek 1992; Wilson *et al.*, 1997). Dosage forms using pH-sensitive polymers and hydrogels have also been used for the drug targeting to desirable pH (Saffran *et al.*, 1986; Chiu *et al.*, 1999; Khan *et al.*, 1999). Some other

approaches such as conjugation with glycoside, glucuronide, cyclodextrins, dextrans, amino acid and time-release system and bioadhesive systems have also been reported for the colonic drug delivery by Chourasia and Jain (2003). Impermeability of the colonic epithelia for drugs and long transit time of the colon are the major limitations for colonic drug delivery (Sangalli *et al.*, 1999; Lee and Yang, 2001; Washington *et al.*, 2001).

1.2.1(g) General use of particulate drug carriers

The colloidal particulates are becoming increasingly prominent in the novel drug delivery systems because of their potential for drug delivery, targeting, protecting gastric labile drugs and in parallel, protecting the GIT from drug toxicity and capacity for permeation into membranes (Ferrari, 2005). They are translocated in enterocytes, Peyer's patches and M-cells simultaneously by para- and intra-cellular pathways and subsequently, gain access to lymphatics (Walgren *et al.*, 2000; Feng *et al.*, 2002). Several particulate carrier systems have been described including liposomes, nanoparticles, microparticles, microspheres, dendrimers and Ferro fluids (Artursson *et al.*, 1984; Levy and Andry, 1990; Fournier *et al.*, 1994; Jameela and Jayakrishnan, 1995). In accordance with the scope of the present study, the particulates will be emphasised more in Section 1.3.

1.3 PARTICULATE DELIVERY SYSTEMS

There is no agreed international definition of a nanoparticle, though Kreuter (1983a), Couvreur *et al.* (1986) and Allemann *et al.* (1993) have defined nanoparticles as the particles ranging in size from 10-1000 nm. A review of the internet (<http://www.sciencedirect.com> accessed on 27 May, 2006), revealed that the majority of the researchers are partial towards the above definition. However, according to the document PAS71 by Publicly Available Standard in collaboration with British Standards Institution, a nanoparticle is a particle having one or more dimensions of the order of 100 nm or less with the properties different from that of the bulk material (<http://www.malvern.co.uk>; accessed on 27 May, 2006). The nanoparticles are typically made of a single material in which a drug is entrapped,

encapsulated or adsorbed onto the surface (Kreuter, 1993; Kreuter, 1994). Generally, the spherical formulation with a particle size above 1 μm , with a distinguishable coating and core regions are referred to as microcapsules while matrix type structures are the microspheres or microparticles. Micelles are self-assembled block copolymers that form a hydrophilic layer and an inner hydrophobic core or vice versa. Dendrimers are monodispersed symmetric macromolecules with a large number of reactive end groups (Passirani and Benoit, 2005). The terms used to describe particulate carriers vary among the authors but herein the “particulate” will collectively be used for the systems of colloidal particulate intended for drug delivery. However, the references sustain the original terminology used by the authors.

1.3.1 Liposomes

Liposomes are microscopic vesicles composed of one or more lipid bilayers surrounding an aqueous space (Gregoriadis, 1991). Phospholipids are the most commonly used materials of fabrication for liposomes (Knight, 1981; Barratt, 2000). Both water and lipid soluble drugs can be entrapped within the aqueous compartment or lipid bilayers, respectively (Betageri *et al.*, 1993a; Sharma and Sharma, 1997). Surface modification has improved the stability of liposomes in the gut and has facilitated permeation of drugs from gastrointestinal mucosa (Morgan and Williams 1980).

Liposomes protect drug against enzymatic degradation and improve drug hydrophilicity (Al-Meshal *et al.*, 1998; Bayomi *et al.*, 1998; Weiner and Chiang, 1988; Kisel *et al.*, 2001). Liposome-entrapped cefotaxime sodium has been reported to be a potential delivery system for oral route as indicated by its enhanced bioavailability (Betageri *et al.*, 1993b; Rojers and Habib, 1999; Ling *et al.*, 2006). The phospholipids are readily hydrolysed or oxidised, thus liposomes require storage under nitrogen atmosphere. The liposomes are not compatible with several coatings of surfactants and are instable against the bile salts (Betageri *et al.*, 1993c; Sharma and Sharma, 1997).

1.3.2 Solid lipid nanoparticles

Solid lipid nanoparticles (SLNs) are the colloidal carrier for lipophilic drugs and composed of a high melting point lipid as a solid core coated with surfactants (Gassco, 1993; Muller *et al.*, 1995; Chen *et al.*, 2001). SLNs, the promising alternative delivery system to emulsions, liposomes and polymeric nanoparticles, can be administered through parenteral, oral or dermal route (Siekman and Westesen, 1992; Gassco, 1993) and share all the advantages of above in one carrier (Schwarz and Mehnert, 1999; Muller *et al.*, 2000).

1.4 GENERAL METHODS FOR PREPARATION OF PARTICULATES

Nano- and microparticulates are formed by bottom-up or top-down procedures, the former procedure being used more frequently. In bottom-up procedure, the particulates are produced by polymerisation of monomers (dispersion polymerisation) or by shaping or condensation of macromolecules (coacervation, spray-drying, or solvent evaporation).

1.4.1 Bottom-up procedures

1.4.1(a) Emulsion/dispersion polymerisation

In emulsion-polymerisation, particles are formed by chemically induced polymerisation of monomers dispersed in a continuous phase (Kreuter, 1983a). The polymerisation media may be aqueous or organic, employed for water-insoluble and soluble monomers, respectively (Gassco and Trotta, 1986; Krause *et al.*, 1986). The polymer, on reaching certain molecular weight, form particles and becomes insoluble, leading to phase separation (Kreuter, 1982). The chemical initiator may be ammonium or potassium peroxodisulphate, bases or basic drugs (Kreuter, 1990; Kreuter 1992).

The surfactants solubilise or disperse the insoluble monomers in continuous phase and stabilize the particulates while the cross-linker links the monomers (Schwartz and Rembaum, 1985). Emulsifiers are not mandatory for a hydrophilic macromolecule since it acts as dispersant (Kreuter, 1983a; Al-Khouri Fallouh *et al.*, 1986). The drugs can either be

incorporated in particles during polymerisation process or adsorbed onto the formed nanoparticles (Allemann *et al.*, 1993). The limitations of the applications are the conditions and solvents with respect to the stability of incorporated drug, drug-polymer reaction and the practically difficult removal of contaminants, un-reacted monomers or reaction initiator residues from the product (Fessi *et al.*, 1989; Quintanar-Guerrero *et al.*, 1996).

1.4.1(b) Preparation from preformed polymers

Use of the preformed and biodegradable macromolecules to prepare particulate carriers may prevent the problems associated with emulsion-polymerisation method. The principal methods for production of particulates from preformed polymers are emulsification-solvent evaporation, precipitation, or denaturation (Tice and Gilley, 1985; Fessi *et al.*, 1989). Solvent evaporation is usually referred to as the phase separation when a water insoluble polymer is in question, while the term coacervation is used for separation of water-soluble macromolecules (Fessi *et al.*, 1989; Jeffery *et al.*, 1991; Jeffery *et al.*, 1993).

I Emulsification-solvent evaporation

In the emulsification-solvent evaporation, a polymer dissolved in a water-immiscible volatile organic solvent is emulsified in the aqueous medium to form oil-in-water emulsion. The subsequent evaporation of the organic solvent, by heating or reduced pressure solidifies the organic phase droplets to particles. Drug is incorporated during the production as dissolved or suspended in the polymer solution in the organic solvent (Tice and Gilley, 1985; Al-Khoury Fallouh, 1986). The final product may require centrifugation, washing and lyophilisation (Krause *et al.*, 1985; Jeffery *et al.*, 1991).

Double emulsion solvent-evaporation, a modification of the emulsification solvent technique improves the loading efficiency of hydrophilic drugs but yields relatively larger particle size. In this approach, an aqueous drug solution is first emulsified in an organic solution of polymer to yield primary emulsion, which then is poured to the larger volume of

aqueous phase (Blanco-Prieto *et al.*, 1994; Rafati *et al.*, 1997; Delie *et al.*, 2001). Limitations of the method are the same as those mentioned for emulsion polymerisation (Verrecchia *et al.*, 1995).

II Coacervation (phase separation) method

Coacervation involves a separation of a polymer from its solution and deposition around a drug to be coated. In this process, a synthetic polymer is dissolved in a water-immiscible organic solvent and the separation is induced by the addition of another organic solvent or oil (Ruiz *et al.*, 1989; Sampath *et al.*, 1992). The polymer may also be dissolved in a water miscible solvent and then poured into a non-solvent (usually water with surfactant). The polymer separation is also induced by a change of surface charge by ionic gelation, temperature, or pH and addition of salt (salting out) or incompatible polymer (Calvo *et al.*, 1997). Addition of desolvating agents causing the so-called salting out phenomenon can also be used to form coacervate. The organic solvent is evaporated under a reduced pressure (Oppenheim *et al.*, 1984). Hardening is achieved by addition of a cross-linker, thus, purification from hardening agent is a disadvantage of this method (Fessi *et al.*, 1989). Recently, a complex coacervation or polyelectrostatic complexation method has been reported for the preparation of nanoparticles in which the polymer-polymer or polymer-drug complex is formed by electrostatic interactions (Liu *et al.*, 2007; Bayat *et al.*, 2008a; Bayat *et al.*, 2008b).

1.4.1(c) Solvent deposition/displacement (nanoprecipitation)

Nanoprecipitation is a simple, one-step and straightforward technique for preparation of nanoparticles. It is carried out with two miscible solvents, the first one must be the solvent ideally for both polymer and drug while the second is a non-solvent for both. Addition of polymer solution to the non-solvent leads to nanoprecipitation by a rapid diffusion of polymer-containing solvent into the dispersing medium (also called desolvation of polymer). The drug is encapsulated in the polymer (Fessi *et al.*, 1989; Bilati *et al.*, 2005).

1.4.1(d) Emulsification-cross-linking

In this method, the aqueous solutions of polymer and of the drug to be incorporated into the particles are emulsified in oil, which result in the formation of droplets. The droplets can then be hardened by addition of cross-linkers or by denaturation of the molecules at high temperatures (Gupta *et al.*, 1986; Kreuter, 1992). The addition of surfactants stabilizes the emulsion and helps re-suspension of the final dry nanoparticles in water (Widder *et al.*, 1979; Gupta *et al.*, 1986).

1.4.1(e) Desolvation of macromolecules

Particles can be produced after dissolution of relatively hydrophilic copolymers or macromolecules in water-miscible solvents. The solutions of the polymer and of the drug to be entrapped in the above solvents are then poured into water, resulting in the spontaneous formation of particles due to desolvation. The particles produced by this method however, are not redispersible in water after spray- or freeze-drying (Bodmeir *et al.*, 1991). Addition of desolvating agents results in precipitation of macromolecules or coacervation as a new phase. The polymer may be gelatine, human serum albumin, bovine serum albumin, casein and ethyl cellulose. In some cases, surfactants are required in order to solubilise certain drugs or to facilitate the redispersion of the final freeze-dried product (Marty *et al.*, 1978).

1.4.2 Supercritical fluid technology

Use of organic solvents/or some chemical reaction stabilizing the colloid structure and thus, the need of extensive purification can be avoided by use of supercritical fluid technology. The supercritical fluid technology yields organic solvent-free and pure particles thus, is highly environment-friendly. In this technology, the solution of material of interest in a supercritical fluid is expanded through a nozzle. An abrupt decrease in the solvent power on expansion results in precipitation of solute (Tom and Debenedetti, 1991). Nevertheless, insolubility of polymers (MW >10,000 D) in supercritical fluid had made this technique impractical (Tom *et al.*, 1994).

1.4.3 Top-down procedure

Top-down procedures employ the physical energy or stress to reduce the particle size of a coarse polymer. Extrusion and wet-grinding (nanomilling) are the two common physical methods and require the coarse polymer to be grinded in a dispersion medium containing surfactants, stabilizers and other adjunctive materials. Size reduction is achieved by shearing forces (tearing apart), influencing forces (crushing and impinging) and attrition (tearing-impacting combined) (Yilmaz *et al.*, 2001).

1.4.3(a) Extrusion

Extrusion is employed by an instrument, called extruder that has two counter rotating screws through which the material is passed to reduce the size (Patent No WO 00/40617, 2000). Extrusion is cost effective, environment-friendly technology and thus, is an attractive method to encapsulate a great variety of bioactive substances in starch matrices. Yilmaz *et al.* (2001) has comprehensively reviewed the use of extrusion for this purpose. Perhaps, use of a higher volume is a dominating reason for its limited use in the current research.

1.4.3(b) Wet-grinding (nanomilling)

Wet-grinding or nanomilling, using media-mills requires small volume, this coupled with efficiency in reducing the particle size and use of wet-grinding is gaining attraction in size reduction. So far, application of the wet-grinding has been confined only to the material research and there are a few reports on its use for pharmaceutically applicable nanomaterials (Merisko-Liversidge *et al.*, 1996; Merisko-Liversidge *et al.*, 2003).

1.4.4 Materials of fabrication of particulates

Natural polymeric materials or their derivatives such as dextran, maltodextrin, mannan, or other starch derivatives, albumin and gelatine have been studied for developing particulate delivery systems (Schroder *et al.*, 1985; Artursson *et al.*, 1987; Artursson *et al.*,

1988; Fahlvik *et al.*, 1990). However, the synthetic polymeric materials are usually preferred due to their consistent properties, biodegradability, biocompatibility and compatibility with drugs. Copolymers such as poly (lactic-co-glycolic acid) or poly(lactic acid)-polyethylene oxide, have been well-documented (Vert, 1986; Kissel and Koneberg, 1996). Majeti and Kumar (2000) reviewed materials currently used in preparation of particulate materials. Some of the synthetic materials are costly while others have some degree of toxicity (Kreuter, 1992; Kreuter, 1993; Kreuter, 1994). Several features of starch, stated in Section 1.6.4 have motivated the use of starch as the fabrication material.

1.5 GENERAL APPLICATIONS OF PARTICULATES

1.5.1 Oral delivery of peptides, gastrolabile drugs and vaccines

Presenting the gastric instable drugs in particulates offers gastric stability, improves cellular uptake and due to their access to lymphatics, avoids first pass effects (Gautier *et al.*, 1992; Bayat *et al.*, 2008a Bayat *et al.*, 2008b). Particulate-bound gastric labile and water insoluble drugs exhibit enhanced bioavailability (Eldridge *et al.*, 1990; Jani *et al.*, 1992). Recently, Pereira (2008) demonstrated an enhanced absorption of Eudragit-loaded cefotaxime sodium in rats. A drug in nanoparticles may have a long-term effect due, in part to the formation of a depot in the gut wall, Peyer's patches, lymphatic system and/or other body compartments (Grangier *et al.*, 1991).

1.5.2 Targeting infected and inflamed cell

The nanoparticles are readily taken up by phagocytic cells, Kupffer cells and monocytes (Lam and Mathison, 1982), making targeting possible for nanoparticle-bound drug to these cells and the alveoli with an improved drug efficacy (Eltahawy, 1983). The infected reticuloendothelial system (RES) cells with human immunodeficiency virus or leishmaniasis and inflamed cells show preferentially higher phagocytosis of nanoparticle-bound drugs (Mizushima, 1985; Fouarge *et al.*, 1989; Meltzer *et al.*, 1990; Losa *et al.*, 1991).

1.5.3 Targeting cytostatics to tumours

The particulates accumulate in a number of tumours, may be due to their increased bioadhesiveness towards the tumours (Gipps *et al.*, 1986; Alpar *et al.*, 1989; Illum *et al.*, 1989). It may also be attributed to endocytosis of particles by endothelial cells lining the tumour vasculature or escape of particles through leaky or open blood vessels (Couvreur *et al.*, 1982; Widder *et al.*, 1983; Gupta *et al.*, 1989). Nanoparticles have prolonged persistence time in a variety of tumours and metastases with enhanced efficacy and decreased toxicity of a number of cytostatics (Brasseur *et al.*, 1980; Couvreur *et al.*, 1986; Ferrari, 2005).

1.5.4 Ophthalmic delivery

Ocular drug in a particulate delivery system increases the residence time of drug as compared to the conventional ocular delivery systems that have fast washout due to rapid tear turnover, lachrymal drainage and dilution of tears (Lee and Robinson, 1979; Losa *et al.*, 1993; Zimmer *et al.*, 1995). The persistence time of drug can be further enhanced by using a strong bioadhesive substance for nanoparticle fabrication (Gurny *et al.*, 1987).

1.5.5 Vaginal drug delivery

Microparticulate systems have been investigated for drug and vaccine delivery through vaginal mucosa (Okada, 1991; Hagan *et al.*, 1993). Starch microspheres, 40 μm in diameter, were shown to be capable of enhancing the vaginal absorption of insulin (Okada, 1991).

1.5.6 Enhancing drug safety

Due to the selective localisation in the infected cell and tumours, the particulate drug delivery systems reduce drug delivery to the non-targeted tissues (Lam and Mathison, 1982; Eltahawy, 1983). Thus, such systems have potentials to improve efficacy, safety and reduce the chances of drug resistance (Fouarge *et al.*, 1989; Schafer *et al.*, 1992).

1.5.7 Adjuvants for vaccines

Nano- and microparticles claim most of the desired features that the vaccine carriers must have (Wikingsson and Sjöholm, 2002), thus are promising for use as adjuvant for vaccines (Chen *et al.*, 1998; Singh *et al.*, 2000; Briones *et al.*, 2001). Their slow degradation offers long persistence in body, prolonged contact of antigen with immunocompetent cells and thus able to maintain a long immunity (Kreuter *et al.*, 1986; Hedley *et al.*, 1999; Herrman *et al.*, 1999; Cui and Mumper, 2003).

1.6 STARCH AS THE MATERIAL OF PARTICULATE FABRICATION

Starch, the material of fabrication for particulate carrier in this study is the major carbohydrate reserve in plant. It is a semi-crystalline material extracted from a variety of sources, maize being the predominant followed by wheat potato and rice barley (Buléon *et al.*, 1998; De-Baere, 1999; Gordon, 1999; Wesslén and Wesslén, 2002). Chemically, starch is a polysaccharide that consists of repeating glucose units (Li and Yeh, 2001; Singh *et al.*, 2003). Starch is abundantly available, cheap and is widely used polymer. The properties of native starch, being dependent upon the source are inconsistent but the commercially available starch is with consistently uniform quality (Gordon, 1999) as freely flowing white coloured powder.

Starch has found diverse and wide range of applications in pharmaceutical and non-pharmaceutical fields. It is used as staple food, raw material (Aime *et al.*, 2001), source of energy (calories), thickener, gelling agent (Aime *et al.*, 2001; Tester and Karkalas, 2002) and as a dietary fibre (www.lsbu.ac.uk/water/hysta.html; Accessed on 7 December, 2005). In pharmaceutical field, starch is used conventionally as a thickener, tablet binder, diluent, disintegrant, stabilizer, gelling agent and as a drug carrier. In topical preparations, it is used as dusting-powder for its absorbency, as a protective covering in ointment formulations and as an emollient (Bayazeed *et al.*, 1989; Whaley *et al.*, 1999; Schmidt *et al.*, 2001; Jeffcoat *et al.*, 2002; Lind *et al.*, 2002).

1.6.1 Starch composition and molecular structure

Though varied in structure and composition, each starch granule primarily contains blends of two polyglucans, amylose and amylopectin, both being associated through hydrogen bonding and arranged in layers to form granules (Hovenkamp-Hermelink *et al.*, 1987; Tomlinson *et al.*, 1997; Li and Yeh, 2001; Vorwerk *et al.*, 2002).

1.6.1(a) Amylose

Amylose is mostly linear fraction consisting of about 500 – 20000 α -D-glucose units linked through α (1 \rightarrow 4) linkage and accounting for 20-30 % of the total starch (Li and Yeh, 2001). It has lower molecular weight (10^5 – 10^6 g/mol) but has a relatively extended shape with radius of 7-22 nm and generally tends to wind up into single or double helical junction zones. Hydrogen bonding is also present between the aligned chains (Morrison *et al.*, 1986; Morrison *et al.*, 1993a; Hoover, 2001).

1.6.1(b) Amylopectin

Amylopectins are branched fractions containing short chains linking linear chains via α (1 \rightarrow 6) linkages, forming branching point at one residue in every twenty and some cases, every thirty residues, thus making it a huge but compact molecule with molecular weights between 10^6 and 10^7 g/mol (Hoover, 2001; Li and Yeh, 2001). Each amylopectin molecule contains up to two million glucose residues and has a hydrodynamic radius of 21-75 nm (Parker and Ring, 2001). It accounts for 70-80 % of total starch. Hydrogen bonding between sequential residues encourages a helical conformation in amylopectin (French *et al.*, 1984; Li and Yeh, 2001; Parker and Ring, 2001).

1.6.1(c) Molecular arrangement of amylose and amylopectin

Amylose and amylopectin molecules are oriented as alternating semi-crystalline (dark) and amorphous layers, forming concentric regions in granules. In semi-crystalline layer, the ordered regions compose of double helices of short amylopectin branches. The

amorphous regions of the semi-crystalline layers and the amorphous layers are composed of amylose and non-ordered amylopectin branches (Yamaguchi *et al.*, 1979; Jenkins *et al.*, 1993; Donald *et al.*, 1997; Gallant *et al.*, 1997; Baldwin *et al.*, 1998; Baker *et al.*, 2001; Parker and Ring, 2001).

1.6.1(d) Other minor components

Starch may have some minor components such as lipids, fatty acids, phosphorus and proteins (Morrison, 1993a; Lim *et al.*, 1994; Hizukuri *et al.*, 1996; Jane *et al.*, 1996; Ellis *et al.*, 1998; Tester and Karkalas, 2002).

1.6.2 Types of starches

Based on source, the starches are grouped as corn (maize), potato, rice, tapioca and wheat. Depending on contents, starches are waxy when the amylose to amylopectin ratio is low ($\approx 15\%$), normal when amylose represents $\approx 16-35\%$ and high-amylose when amylose content exceed $\approx 36\%$ (Morrison, 1993b). The common corn starch has 25% amylose while the waxy corn starch is almost totally made up of amylopectin. The granules of high-amylose starch tend to be smooth and have a narrower size range. Potato starch has about 20% of amylose (Jane *et al.*, 1994).

1.6.2(a) Modified starches

Starch is modified to enhance and expand its functionality and is achieved chemically, enzymatically, physically, or by biotechnological approach due to rupture of all or part of starch granules (Jobling, 2004). Physical modification can be achieved by milling to produce damaged starch granules. Pregelatinised starch is obtained using a physical method by the simultaneous gelatinisation and drying of aqueous starch dispersions. In this process, heating of starch in excess water induces many physical changes such as loss of crystallinity, swelling and rupturing of starch granules (Blanshard, 1987; Tester, 1997). Gelatinised starch is easily dispersed in cold water. Extrusion of starch is another physical

method (Giezen *et al.*, 2004). Other methods include enzymatic modification by α - β -amylase and amyloglucosidase are used to hydrolyse starch. The cross-linked starches are produced by chemical modification (Tester and Karkallas, 2002).

1.6.3 Functionality of starch

1.6.3(a) Gelatinisation

On heating starch in excess water, starch granules absorb water and while hydrogen bonding between amylose and amylopectin maintains granule integrity, it begins to swell from hilum (centre). Granules lose organised structure, crystallinity and become amorphous. Ultimately, granule structure is completely lost resulting into a thin paste (<4 %) or gel (>4 %). Typically, this process begins at 45°C, peaks at 60°C and completes at 75°C. Gelatinisation renders starch easy deformation and complete digestibility. Degree of swelling dictates the extent of starch water binding capacity (Jane *et al.*, 1996; Li and Yeh, 2001; Rosa, 2004; Tester *et al.*, 2004). After gelatinisation starch, which is otherwise water insoluble, becomes water soluble (Dziechciarek *et al.*, 1998; Jane *et al.*, 1999; Tester and Sommerville, 2003). The common solvents for starch are sodium or potassium hydroxide and dimethyl sulfoxide (Radosta *et al.*, 2001). Higher amylose content, owing to the extensive hydrogen bonding, requires more energy to gelatinise the starch. Thus, high amylose starch have less swelling power and higher gelatinisation temperatures (Li and Yeh, 2001; Singh *et al.*, 2003). The presence of phosphate groups in starch increases its swelling power. Certain salts such as calcium chloride and lithium chloride promote gelatinisation of starch at room temperature (Jane, 1994; Jane *et al.*, 1999; Pan and Jane, 2000).

1.6.3(b) Hydrocolloidal functionality

Starch functions as hydrocolloid due to the presence of amylose and amylopectin. The extended and loose helical amylose chains have a relatively hydrophobic inner surface. Similarly, helical structure in amylopectin may present continuous hydrophobic surface (King, 1995; Whaley, 1999).

1.6.3(c) Thickening agent

Viscosity is purely a function of molecular weight of substances. The branched structure of amylopectin with all attached chains yields much larger molecule than amylose. Consequently, it builds higher viscosity thus the waxy starches have higher viscosity. Amylopectin interferes with the interaction between amylose chains and its solution that can lead to an initial loss in viscosity followed by a more slimy consistency. After gelatinised, the swollen granules increase the viscosity of dispersion (Bayazeed *et al.*, 1989).

1.6.3(d) Gel and film formation

In a solution, amylose molecules easily align themselves with one another and associate through hydrogen bonding to form gels or films. This property is useful for several applications such as coating and for the inclusion of fats and flavours in starch (Shinsato *et al.*, 1999). In general, higher degree of polymerisation (length of amylose in starch) gives greater gel strength due to its increased ability to associate through hydrogen bonding. High amylose starches show better film forming properties. Gelatinisation creates more tendencies for association of granules to form gels and films (Roper and Koch, 1990; Zeller *et al.*, 1999; Haugaard *et al.*, 2001).

1.6.3(e) Retrogradation

Tendency of re-association of the gelatinised starch molecules with one another on cooling and thereby, forcing water out of the molecule, causing starch to recrystallise is called retrogradation. This unique property of starch is due to the presence of amylose. Branched amylopectin impedes retrogradation but the long branched amylopectin are susceptible to retrogradation. Mixing with carrageenan, alginate and xanthan gum and low molecular weight sugars can reduce retrogradation. On release of water, the aligned chains may form double stranded crystallites that are resistant to amylase and due to extensive inter- and intra-strand hydrogen bonding makes hydrophobic structure of low solubility (Shogren *et al.*, 1992; www.lsbu.ac.uk/water/hysta.html: Accessed on 7 December, 2005).